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Asthma is a heterogeneous disease with many phenotypes, and age at disease onset is an important factor in separating the
phenotypes. Most studies with asthma have been performed in patients being otherwise healthy. However, in real life, comorbid
diseases are very common in adult patients.We review here the emerging comorbid conditions to asthma such as obesity, metabolic
syndrome, diabetes mellitus type 2 (DM2), and cardiac and psychiatric diseases. Their role as risk factors for incident asthma
and whether they affect clinical asthma are evaluated. Obesity, independently or as a part of metabolic syndrome, DM2, and
depression are risk factors for incident asthma. In contrast, the effects of comorbidities on clinical asthma are less well-known
and mostly studies are lacking. Cross-sectional studies in obese asthmatics suggest that they may have less well controlled asthma
and worse lung function. However, no long-term clinical follow-up studies with these comorbidities and asthma were identified.
These emerging comorbidities often occur in the samemultimorbid adult patient andmay have in commonmetabolic pathways and
inflammatory or other alterations such as early life exposures, systemic inflammation, inflammasome, adipokines, hyperglycemia,
hyperinsulinemia, lung mechanics, mitochondrial dysfunction, disturbed nitric oxide metabolism, and leukotrienes.
1. Introduction
Asthma is a common chronic disorder affecting more than
300 million people all over the world with prevalence among
adults varying between 0.2 and 21% [1]. Recently, the cluster
studies have revealed that asthma is not a single disease but
a heterogeneous syndrome manifesting with distinct pheno-
types. Age at asthma onset has emerged as a critical factor
in distinguishing between phenotypes [2–4]. Patients with
early-onset (or childhood-onset) asthma are typically atopic
withTh2-predominant inflammation, good responsiveness to
glucocorticoids, and good prognosis [5]. In contrast, patients
with adult- or late-onset asthma are often nonatopic, are
females, have less favourable prognosis, and are more likely
to develop persistent airflow limitation [2–4, 6, 7]. Most of
asthma is thought to start during childhood. However, this
has recently been challenged by showing that, in United
States, adult-onset asthma is the dominant phenotype in
women from 40 years of age [8]. Adult-onset asthma and
adult-onset phenotypes have been associated with factors
such as female sex, obesity, occupational exposure, rhinitis,
respiratory infections, smoking, stressful life events, and
low level of lung function [2–4]. As recently reviewed in
this journal [4] the mechanisms of adult-onset asthma may
include severalmetabolic and inflammatory components that
are common to the other diseases such as obesity, metabolic
syndrome (MBO), diabetes mellitus type 2 (DM2), cardio-
vascular diseases (CVD), and psychiatric diseases.
Most clinical trials with asthma have been performed
in patients being otherwise healthy. However, in real life,
comorbid diseases are very common, especially in adult and/
or aging patients. For example, in the US 35% of adult people
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Figure 1: Emerging comorbidities in asthma.
are obese [9]. In addition, it is rather a rule than exception that
patients not only often present with one comorbid disease
but also have several comorbidities, that is, suffering from
multimorbidity [10–12].
In early-onset childhood asthma, food allergies, atopic
eczema, and allergic rhinitis are common and well-
characterized comorbidities [13–16]. Some other comorbid
conditions such as gastroesophageal reflux have gained a lot
of attention during the years [17–19]. The role of these com-
orbidities has been thoroughly reviewed elsewhere [13–20].
Chronic obstructive pulmonary disease (COPD) is usually
affecting age groups of 40 years and older. Asthma andCOPD
share many clinical features both being chronic obstructive
airway diseases but having variable degrees of reversibility
of airway obstruction [21]. The coexistence of asthma and
COPD or the recently characterised asthma-COPD overlap
syndrome (ACOS) has been reviewed and characterized in
treatment guidelines of both asthma and COPD, for example,
in Global Initiative for Asthma (GINA) and Global Initiative
for Chronic Obstructive Lund Disease (GOLD) reports and
in some national guidelines [22–26].Thus, COPD and ACOS
will not be covered by the present review.
In this review, we aim to give the reader an overview of
the emerging comorbid conditions to asthma such as obesity,
MBO, DM2, CVD, and psychiatric diseases (Figure 1). We
focus on asthma in adults and especially on adult-onset
asthma if evidence is available. We have five separate aims in
this review if such data is available: (A) to characterize the
epidemiological evidence how these comorbidities associate
with asthma, (B) to describe the role of the comorbidity as a
risk factor for incident asthma, (C) the possible role of asthma
as a risk factor for the incident comorbidity, (D) the effect of
the comorbidity on the clinical outcome of asthma, and (E)
to describe the possible common mechanisms that may link
asthma and the abovementioned comorbid conditions.
2. Epidemiologic Studies on
Comorbidities in Asthma
A Norwegian study on 1 239 533 subjects of 8–29 years old
comprised altogether 37 060 asthma patients when asthma
was defined as using filled prescriptions on asthma drugs
[27]. This study showed higher-than-expected occurrence
in all of the diseases studied (attention-deficit hyperactivity
disorder (ADHD), epilepsy, migraine, mental illness, car-
diovascular, autoimmune, gastroesophageal reflux disease
(GERD), allergy, use of antibacterials, and use of antivirals),
except diabetes, in patients with asthma. Fifty-nine percent
of the asthmatics had one or more of these chronic diseases
when the corresponding figure for general population was
18%. In 20–29-year-olds the greatest odds ratios for other
diseases in asthmatics were for allergy (OR 4.8 formen, 4.1 for
women), GERD (OR 3.2 in men, 3.5 in women), and ADHD
(OR 2.3 in men, 2.5 in women). The study population was 8–
29 years old but still showed high prevalence of comorbidity.
In a Canadian population-based study (Ontario, Canada;
population, 12 million) the burden of asthma-associated
comorbidity as measured in rates of hospitalisations, emer-
gency department visits, and ambulatory care claims was
evaluated [28]. Asthma comorbidity-associated ambulatory
claims, emergency department visits, and hospitalisations
were substantial and, in fact, their numbers were much
greater than those due to asthma itself [28]. Interestingly,
the health burden due to asthma comorbidity appeared
substantial regardless of age, gender, socioeconomic status,
or living in a rural or urban area [28]. Approximately half
of the asthma comorbidity claims were for other respira-
tory conditions such as upper respiratory tract infection,
pneumonia, or allergic rhinitis [28]. In a further study by
Gershon and coworkers [29] using the same Ontario data,
comorbidity was evaluated as indicated by use of health
service in 14 disease categories. In patients with asthma,
comorbidity was 46% (0–4 years old), 40% (5–17 years old),
47% (18–44 years old), 49% (45–64-years old), and 22% (65
years old or more) higher than in those without asthma [29].
In all age groups most of the 14 disease categories were more
common in patients with asthma. The highest comorbidity
(50% or more) was found for respiratory disease other
than asthma, psychiatric disorders, metabolic and immunity
disorders, and perinatal disorders (0–4 years old). Risk of
respiratory disease (other than asthma) was approximately
double, and risk of psychiatric disorders and infectious
diseases was approximately 33% to 51% higher in individuals
with asthma as compared to those without asthma. In the
oldest age group, physician claims were approximately twice
more common for acute bronchitis and 60% higher for
pneumonia in those with asthma as compared to nonasth-
matics [29].
The results from Great Britain among incident cases of
asthma from primary care were similar showing that patients
with asthma (𝑛 = 7931) have more consultations in all
major organs systems than their age- and gender-matched
nonasthma controls [30]. The mean age of the patients with
asthma in all of the abovementioned studies ranged between
30 and 32 years [28–30] suggesting that a considerable
Mediators of Inflammation 3
proportion of the patients represented asthma beginning
during childhood. Analysis of aged (>65) patients with
asthma suggests that the incidence of comorbidities increases
and more closely resembles that of COPD [30]. Thus, it is
likely that some comorbidity, such as allergy, may be linked
to childhood-onset asthma via common genetic and environ-
mental mechanisms. However, other comorbidities (obesity,
diabetes, depression, and anxiety disorders) may be related
to asthma symptoms (e.g., sleep disturbance contributing to
psychiatric disorders and obesity) or its therapy, for exam-
ple, glucocorticoids inducing systemic adverse effects [31],
diabetes [32], or increased risk for pneumonia [33].
A German telephone interview study of 2,242 current
asthmatics (1,429 women) of a total of 43,189 study indi-
viduals (18 years or older) evaluated the prevalence of eight
different health conditions (diabetes mellitus, hypertension,
coronary heart disease, chronic heart failure, stroke, cancer,
osteoarthritis, and depression) in patients with asthma as
compared with those not having current asthma [34]. All of
these eight health conditions were more prevalent in patients
with asthma. Almost every fifth of the patients with asthma
(17.8%) had at least 3 chronic conditions whereas 8.0% of con-
trols with no current asthma had at least 3 chronic conditions.
Interestingly, multimorbidity (i.e., three or more chronic
conditions) was associated with increased risk for unsched-
uled inpatient care (OR 3.4) and for unscheduled outpatient
care (OR 2.3) [34].
An analysis of Finnish public sector employees [35]
reported that asthma increased the risk of all-cause long-term
(sickness absence or disability pension >90 days) work dis-
ability (HR 1.8) as compared to controls (no asthma). How-
ever, asthma and one chronic comorbid condition increased
the risk for long-term all-cause work disability with HR 2.2
and asthma together with two or more chronic conditions
increased the risk with HR 4.5 [35]. According to the study
results asthma is a minor risk for long-term work disability
but asthma with multiple comorbidities is a major risk.
Aging increases morbidity and also multimorbidity in
patients with asthma [12]. By nomeans,multimorbidity is not
a unique feature of asthma but rather represents clustering of
diseases to certain persons. In fact, out of the 40 conditions
studied in large analysis in Scotland [10], there was no condi-
tion inwhichmost people had that condition only [12].Multi-
morbidity is generally associated with increased risk formen-
tal health disorders [10, 11]. Further, socioeconomic depriva-
tion is associated with multimorbidity suggesting clustering
of social, economic, and health problems in certain individ-
uals or in certain areas. Taken together, comorbidity is com-
mon in asthma; allergy and obesity are common in younger
age groups, whereas obesity, diabetes, GERD, and psychiatric
and cardiovascular diseases are found in older age groups.
Respiratory infections are found in all age groups.
3. Obesity
3.1. Is Obesity Associated with Asthma? Does Obesity Increase
the Risk of Asthma? The studies evaluating the association
between obesity and asthma use generally body mass index
(BMI) as a tool. A BMI ≥ 25 is considered overweight, while
people with BMI ≥ 30 are classified as obese. BMI is particu-
larly useful as it is standardized, calculated in the sameway for
both sexes and for adults of all ages [36].
Obesity is a risk factor for asthma, especially among
women [37, 38]. A meta-analysis has been performed on the
risk [17].The risk for asthma was 1.20 for overweight and 1.43
for obese men. The corresponding risk estimates for women
were 1.25 for overweight and 1.78 for obesity [17]. Also recent
large US and Norwegian epidemiological studies report odds
ratios ranging from 1.29 [39] to 1.84 [40] for obese males and
1.55 [39] to 1.96 [40] for obese females to have or to develop
asthma as compared with their normal weight counterparts.
What does this mean in real life? A 25-year follow-up in
the Coronary Artery Risk Development in Young Adults
(CARDIA) cohort gives us an approximation. Approximately
1 out of 4 obese women followed up from the age of 25 devel-
oped asthma during the 25-year follow-up period, whereas
approximately 1 out of 7 normal weight women developed
asthma [41].
Does increasing obesity increase the risk of asthma? A
recent large US epidemiological survey reported an associ-
ation with the self-reported doctor-diagnosed asthma and
the class of obesity. In class I (BMI 30–34.9) obesity OR for
asthma was 1.27, in class II (BMI 35–39.9) obesity OR was
1.55, and in class III (BMI ≥ 40) OR was 1.85 indicating a
positive association between the degree of obesity and asthma
[39]. Similarly, a large Norwegian cohort [40] reported an
increased odds ratio for asthma with increasing BMI (per
5 kg/m2) in females (OR 1.32) and in males (OR 1.38). In the
US based survey [39] a sex difference was reported by show-
ing that class III obesity is significantly more strongly associ-
ated with asthma in women (OR 2.11) than in men (OR 1.40).
Similarly, a much less pronounced risk for the development
of asthma was seen between normal weight and obese men
in the CARDIA study [41]. However, the effect of obesity on
the development of asthma may depend on the asthma phe-
notype. In the long-term follow-up of children hospitalised
because of bronchiolitis and many subsequently developing
asthma, obesity did not affect the development of asthma in
this small cohort [42].
Although cross-sectional studies or follow-up of certain
cohorts in adults has demonstrated an increased prevalence
of asthma in obese individuals, many of these studies rely
on self-reported weight and height. Another possible limi-
tation of these studies is that most rely on a self-reported
diagnosis of asthma or symptom-based assessment of asthma
rather than on physician records, physiologic evaluation, or
response to inhaled therapy.This raises the possibility that the
respiratory symptoms are related to the physiologic impair-
ment from obesity rather than to asthma [43]. This is espe-
cially important with regard to obesity as obesity increases
the possibility to misdiagnosis of asthma [44, 45]. For exam-
ple, obese subjects who make urgent visits for respiratory
symptoms aremore likely to receive amisdiagnosis of asthma
[44].
Taken together, it appears that obesity is a risk factor for
asthma. In contrast, the role of asthma as a risk factor for
obesity is much less well-known.
4 Mediators of Inflammation
3.2. Obesity and Clinical Asthma. To evaluate the clinical
association between asthma and obesity we evaluated studies
that directly compared asthma-related endpoints in a cross-
sectional or longitudinal study between patients (𝑛 ≥ 50)
being normal weight or obese and reporting at least one
objective measure of lung function. We identified 7 such
studies [44, 46–51] together having 2597 patients with asthma
(Table 1(a)). Even though most of these studies suffer from
a small number of patients and exclude patients with other
comorbidities, they give us an idea what the effect of
obesity on asthma may be. All studies were cross-sectional
and mostly included all severities of asthma. Most studies
excluded smokers and patients with other comorbid states
(Table 1(a)). Patients were adults (mean age between 32 and
57), but the age at the onset of the disease was not reported.
However, in five studies one can assume that the population
contained both patients with childhood- and adult-onset
asthma (Table 1(a)). The large analysis of the Severe Asthma
Research Program (SARP) [47] evaluated the effect of obesity
on asthma parameters separately in early-onset (<12 years)
and late-onset (≥12 years) asthma. The results are not con-
sistent across the studies (Table 1(b)). However, the results
of these studies suggest that obese patients with asthma
are older (Table 1(b)). They possibly present with higher
age at onset and lower control of asthma, use more steroid
courses, experiencemore hospital admissions and emergence
department visits, and have lower lung function although
these differences were not reported in all of these studies.
Three studies [47–49] primarily recruited patientswith severe
asthma. The results of these studies are more consistent with
regard to oral steroid use during previous year, lung function,
and blood eosinophils (Table 1(b)). In support of obese
patients presenting with more severe asthma, the association
of body mass index and asthma severity was evaluated in
the National Asthma Survey in the US [52]. In this large
(𝑛 = 3095) telephone survey obese asthmatics were reported
to present with symptoms all the time over the past 30 days
(OR 1.7), to have greater than 2 missed work days in the past
12 months (OR 1.4), to use inhaled corticosteroid (OR 1.3), to
have GINA medication step 2+ asthma (OR 1.4), to present
with classes II–IV persistent asthma (OR 1.4), and to present
with severe persistent (class IV) asthma (OR 1.4) [52]. In
this cohort, 24% (i.e., almost every fourth) of normal weight
patients were classified to have moderate to severe asthma,
whereas the corresponding figure among obese patients was
35% [52].
These studies (Tables 1(a) and 1(b)) suggest that there
are no differences in inflammatory markers such as blood
eosinophils (four studies, 𝑛 = 1905), FENO (three studies),
high-resolution computerized tomography scan (one study),
and sputum inflammatory cell profiles (one study). In addi-
tion, these studies suggest that other comorbidities such as
GERD, diabetes mellitus, hypertension, and obstructive sleep
apnoea syndrome may be more common in obese asthma
patients, although comorbidities were mostly not analyzed
(Table 1(b)). Interestingly, two studies [47, 51] reported a
reduced probability or tendency of being allergic when being
obese and having asthma. This is in agreement with the
results obtained from cluster studies that suggest that the
recently identified group of patients with adult-onset obese
noneosinophilic asthma phenotype are less allergic/atopic
[2–4].
Further, the SARP study found that the effect of obesity is
different andmore pronounced in early-onset asthma than in
late-onset asthma [47].Thus, asthma beginning in childhood,
when being persistent, might be significantly complicated by
obesity developing later in life whereas asthma beginning
later in adulthood (possibly to the already obese patient) may
not be so much more complicated by obesity as obesity may
already have been a major driving factor in its appearance.
In future, it is of utmost importance to differentiate between
patients having asthma and becoming obese later and obese
patients with new-onset asthma.
In a small Canadian study [46] (Tables 1(a) and 1(b)),
the group of obese asthmatics presented with lower asthma
control and had reduced total lung capacity (TLC), expiratory
reserve volume (ERV), functional residual capacity (FRC),
and residual volume (RV) compared to the normal weight
asthmatics [46]. It is well-known that obesity is associated
with a reduction in ERV and FRC [53–55], but it still remains
contradictory, whether obesity or BMI as such is associated
withmore severe airway obstruction (FEV
1
/FVC) (see Tables
1(a) and 1(b)).
How existing obesity affects the therapy, control, and
prognosis of asthma in a prospective setting? We identified
one 12-month prospective disease management study that
evaluated the impact of obesity in asthma [43]. In children,
there was no relationship between BMI and severity of
asthma, spirometry findings, quality of life (QoL), or health-
care utilization. In adults, there was no relationship between
BMI and asthma severity or health care utilization but higher
BMI was associated with a significant reduction in QoL and
the BMI had an inverse relationship with forced vital capacity
(FVC) [43]. The association of obesity with asthma control
has been analysed in a large asthma population (Kaiser Per-
manente Southern California) (𝑛 = 10,233) [56]. Overweight
and obesity were associated with increased relative risk
for asthma hospitalizations or emergency department visits
(RR 1.4). Obesity was associated with an increased risk for
dispensing ≥ 7 short-acting beta-agonist canisters [56].These
analyses suggest that obesity may have different impact on
asthma in younger age groups than in adults and that obesity
is associated withmore asthma symptoms, reduced TLC, and
poorer asthma control.
3.3. The Effect of Weight Loss on Asthma and the Effect
of Obesity on Pharmacotherapy. Does weight loss improve
asthma control? A randomized study by Stenius-Aarniala and
coworkers [57] showed that weight loss in 38 obese physician-
diagnosed asthmatics is associated with improvements in
asthma symptoms, lung function, and health status. This has
been confirmed in another study [58] showing that dietary
restriction, with or without exercise resulted in a greater ben-
efit in terms of asthma control. Recently, a small controlled
study (𝑛 = 16 + 6) reported that significant weight loss
(from 115 kg → 98 kg/BMI 45 → 36.5) was associated with
a significant improvement in PC
20
(5 → 10mg/mL), FVC%
predicted (94→ 100), asthma control (ACQ score 1.4→ 0.6),
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and asthma quality of life (AQLQ score 5.6 → 6.1) [59]. In
addition, small studies [60–62] have suggested that surgically
induced weight reduction is associated with benefits in
asthma control, symptoms, hyperreactivity, use of medica-
tion, and lung function. Markers of systemic inflammation
(hsCRP, adiponectin, and leptin) were reported to be lower
after bariatric surgery, whereas only a decrease in mast
cells was reported in a group of asthmatics undergoing
bariatric surgery [61]. However, the published studies are
small (actively treated asthma patients together 27 + 23 + 12)
[60–62] and the results suggest that the benefit may diminish
over time [60]. Another factor that makes it difficult to assess
the effect of weight loss interventions on asthma is that
bariatric surgery improves lung function (e.g., FEV
1
, FRC,
and TLC) in obese patients without asthma [61], suggesting
that all improvement is not specific to asthma. A recent
self-controlled case series study [63] of obese patients with
asthma (𝑛 = 2261) and undergoing bariatric surgery gives
hope that weight loss and bariatric surgery are associated
with clear benefits in asthma. Significantly fewer emergency
department (ED) visits or hospitalizations for asthma exac-
erbations occurred within 12 months after bariatric surgery
(11% of patients) compared to during the reference period
(22% of patients) and the risk remained low in the subsequent
period of 13 to 24 months after bariatric surgery (11% of
patients) [63]. In practical terms this means that before
bariatric surgery 22 patients out of 100 experienced ED
visit or hospitalization and after surgery only 11 out of 100
experience such adverse event because of asthma.
Obesitymay also affect the response to the pharmacother-
apy of asthma.The basic choices of pharmacotherapy [22, 31]
of asthma as such are valid also in obese asthmatics. However,
the obese asthmatics may be less responsive to standard
asthma therapy with ICS as compared with normal weight
patients [38] even though the findings are not consistent.
4. Metabolic Syndrome and Asthma
Obesity (high waist circumference) is a major component
of metabolic syndrome, a cluster of metabolic components
that indicate a significantly increased risk of cardiovascular
disease [64]. The other components of metabolic syndrome
include elevated triglycerides, reduced high-density lipopro-
tein (HDL) cholesterol, high blood pressure, and elevated
glucose or diabetes. In contrast, the association of metabolic
syndrome as a syndrome (i.e., not its single components)
with asthma has beenmuch less studied [64].TheNorwegian
prospective cohort of the Nord-Trondelag Health Study from
1995 to 2008 [65] reported thatmetabolic syndromewas a risk
factor for incident asthma (OR 1.6). Among components of
metabolic syndrome, two remained associated with incident
asthma: high waist circumference (OR 1.6) and elevated
glucose or diabetes (OR 1.4) [65]. In the CARDIA study
abdominal adiposity, elevated blood pressure, and impaired
fasting glucose or diabetes were significantly associated with
incident asthma. However, after adjustment for BMI their
significance was lost suggesting that BMI as such is an
independent risk factor for asthma in women [41]. In Korean
40–69-year-old adults, symptoms suggestive of asthma such
as wheezing, resting dyspnea, and postexercise dyspnea were
increased in the subjects of the metabolic syndrome group
[66]. Abdominal obesity and hypertension were the risk
factors for asthma-like symptoms among the components of
the metabolic syndrome [66].
The association between obesity and asthma has been
already largely studied (see above sections) and the associ-
ation between DM2 and asthma will be dealt with separately
in Section 5. Next, we will shortly review the associations
between lipid metabolism and hypertension with asthma.
The complex cholesterol and lipoprotein biology [67, 68] are
outside the scope of the present review and the oversimplistic
“good and bad cholesterol” view does not represent the
whole phenomenon. Although several experimental animal
studies as well as some epidemiological and clinical studies
in children and adolescents [67, 68] suggest an association
between cholesterol/lipoproteins and asthma, surprisingly
few studies have been published on adults with asthma. Two
early studies [69, 70] report conflicting findings in comparing
the cholesterol/lipoprotein profiles in adult patients with
asthma and healthy controls. A very recent study [71] evalu-
ated the levels of apolipoprotein A-I and large high-density
lipoprotein in adult atopic asthma. Serum levels of these
positively correlated with FEV
1
, whereas serum triglycerides,
LDL cholesterol, and apoB were associated with more severe
airflow obstruction [71]. Even though the correlations were
weak and only atopic asthmatics were included (possibly
excluding a larger part of the nonatopic adult-onset asthma
population) in this cross-sectional study, it raises an interest-
ing possibility. It suggests that the atherogenic lipid profile
is associated with reduced FEV
1
in asthma [68] creating an
important link between metabolic syndrome and asthma.
Data from Canadian Community Health Survey with
self-reported or self-reported doctor-diagnosed conditions
has shown in two different studies that patients with asthma
were having approximately 1.4-fold risk for high blood pres-
sure [72, 73]. Similarly, in a sample of JacksonHeart Study, use
of medication for hypertension was more common among
those African American women reporting current doctor-
diagnosed asthma or use of medication to treat asthma
[74]. Taking medication for hypertension was a significant
risk factor for current asthma in this population [74]. A
similar finding has been reported among Arab Americans
[75]. Taken together, there is evidence from the epidemio-
logical studies that hypertension and asthma are connected.
However, there is scarcity of data from clinical studies
whether hypertension complicates asthma or vice versa. A
recent study using Kaiser Permanente Southern California
registry data showed that hypertension is associated with
markers of increased severity of asthma such as use of > 6
canisters of short-acting 𝛽
2
-agonist in a 12-month period,
oral corticosteroid dispensing, and history of emergency
department visits or hospitalizations [76].
Taken together, it still remains unclear whethermetabolic
syndrome itself is a risk factor for asthma or is the risk factor
one (or several) of its components (obesity?). In addition, the
impact of MBO or its therapy on clinical asthma remains
mostly unknown [64].
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5. Diabetes Mellitus and Asthma
Type I diabetes has been suggested to be an autoimmune dis-
ease due to environmental factors, possibly viruses, whereas
type 2 diabetes mellitus has been connected with obesity,
insulin resistance, and systemic inflammation [77–80].
An analysis of the large Kaiser Permanente Medical Care
program has evaluated the risk of asthma among those with
diabetes. In adults (aged ≥ 18 years) with no diabetes age- and
sex-adjusted incidence of asthma was 0.16 per 1,000 person-
years and in those with diabetes the corresponding figure
was 0.41 indicating a higher risk for incident asthma [78].
This association between increased prevalence of asthma
in patients with DM2 has also been confirmed in a large
Danish twin study [79] and in hospitalized patients [80]. The
proposedmechanisms how asthma could increase the risk for
DM2 include genetic pleiotropy, lung-related inflammatory
cytokines and their effects on insulin sensitivity, direct effects
of hypoxia on glucose metabolism, and adverse early-life
exposures and their effects on organ development [81]. In
addition, severe asthma is treated with repeated courses or
persistent per oral glucocorticoids that may increase the
risk of type 2 diabetes [32] even though this has not been
confirmed in other studies [82, 83]. Risk estimates for diabetes
in patients with asthma have varied from 1.3 to 2.1 [81, 84, 85].
Asthma-diabetes association appeared stronger for adult-
versus child-diagnosed asthma cases, and for participants
who were obese compared to those who were nonobese [81].
The current data suggests that a connection between asthma
and DM2 diabetes exists and suggests that both diseases are
able to increase the risk of the other disease. In contrast, the
effect of DM2 on asthma outcome remains unknown.
6. Cardiovascular Diseases and Asthma
Previously connection of asthma and arteriosclerosis has
been evaluated in studies of asthma mortality or in studies
among elderly patients with asthma. Patients with severe
asthma have been reported to have a higher mortality
from ischemic heart disease especially among women [86].
However, such a connection between these diseases has not
been found in elderly asthma patients [69, 87].
6.1. Are Asthma and Cardiovascular Diseases Associated? A
large cross-sectional study (𝑛 = 16,943) looked for the asso-
ciations between adult-onset asthma and CVDs including
stroke, congestive heart failure, and coronary heart disease
[88]. Adult-onset asthma (age of onset ≥ 18 years) was found
to have a significant association with total CVD (OR 2.1).
Only coronary heart disease (CHD) was significantly associ-
ated with adult-onset asthma (OR 2.3). In gender stratified
analyses, only females with adult-onset asthma showed an
increase in the odds for total CVD (OR 2.4) and CHD (OR
2.9). In contrast to expectations, overweight (BMI 25–30)
females with adult-onset asthma had stronger association
with CVD than those having adult-onset asthma and being
obese (BMI > 30) [88]. The limitations of the study were
the cross-sectional setting and definition of smoking history
(nonsmokers or current smokers) thus making exclusion of
COPD impossible [88].
6.2. Does Asthma Increase the Risk of Cardiovascular Diseases?
Over the past decade large cohort studies have been published
to assess the risk of cardiovascular events as asthma comor-
bidities. In a large cohort study of health insurance database
(𝑛 = 151,620) connection of asthma and combined nonfatal
or fatal CHD was assessed [89]. Patients (age ≥ 18 years) with
self-reported physician-diagnosed asthma or hospitalization
due to asthma were followed for 27 years. In women, the
age-adjusted CHD rate was higher in those with asthma
than in those without asthma with a HR of 1.2. Asthma was
associated with the risk of developing CHD in both younger
(<50 years) (HR 1.2) and older (≥50 years) women (HR 1.2).
Asthma among women became significantly associated with
CHD events already after 10 years of follow-up (HR 1.2).
This suggests that women might have a greater biological
susceptibility to the inflammatory asthma milieu or to the
cardiotoxic or metabolic effects of asthma medications [89].
Several studies of the Arteriosclerosis Risk in Communi-
ties (ARIC) cohort have been published concerning asthma
and CVDs as comorbidity [90]. In a prospective study with
14 years of follow-up asthma was modestly associated with
an increased incidence of stroke [91]. In a further study of
the same cohort [92] evaluating the relationship between
asthma and carotid artery intima-media thickness (IMT) also
the age at asthma onset was taken into consideration [92].
The weighted mean for wall IMT thickness for women with
history of adult-onset asthma (≥21 years) was significantly
greater than that of women without asthma. In contrast,
IMT in women with a history of childhood-onset (<21
years) asthma did not differ substantially from nonasthmatic
women. Third study of the ARIC cohort [93] evaluated inci-
dence of CHD and stroke among asthma subtypes (asthma
onset < or ≥ 21 years). Women, but not men, with adult-onset
asthma were found to have a 2-fold increased rate of CHD
compared to their nonasthmatic counterparts.
Iribarren and coworkers [94] followed twomatched adult
cohorts, the other with asthma and a parallel asthma-free
cohort. Both cohorts were followed up for 12 years for inci-
dent nonfatal or fatal CVD and all-cause mortality. Asthma
was associated with a 1.4-fold increased risk of coronary heart
disease, a 1.2-fold risk of cerebrovascular disease, a 2.1-fold
risk of heart failure, and a 3.3-fold risk for all-cause mortality.
Similarly to that found in the ARIC cohort [92, 93] stronger
associations were noted amongwomen, but there was no data
on asthma onset or asthma severity [94]. Among patients
with asthma, 84% used one or more asthma medication
and particularly those using oral corticosteroids alone or in
any combination with asthma medications were at enhanced
risk for developing CVD, which may reflect that that they
were having severe asthma [94]. There remains a possibility
that the medication used may increase the risk of CVD as
especially 𝛽
2
agonists havemany adverse cardiovascular side-
effects and continuous use of glucocorticoids may have many
metabolic disadvantages [89, 94].
Recently, a long-term (10 years) prospective study
reported an association of persistent asthma and CVD events
(coronary death, myocardial infarction, angina, stroke, and
CVD death) [95]. All participants (𝑛 = 6792) were free of
CVD at baseline. Self-reported asthma cases (𝑛 = 667) were
Mediators of Inflammation 9
classified as persistent (daily use of controller medication
such as ICS, LTRA, andOS) in 77% and intermittent (without
controller medication) in 23% of patients. After a decade of
follow-up patients with persistent asthma had a 1.6–1.7-fold
higher risk of CVD events than nonasthmatics. In addition,
markers of systemic inflammation (IL-6, CRP, alfa-dimer,
and fibrinogen) were the highest in patients with permanent
asthma even though patients were using modern controller
asthma medication. Use of controller medication did not
abolish the increased risk of CVD events [95].
Current and former smoking are one of the main risk
factors for both asthma and cardiovascular diseases. Recently
published report [96] from the Copenhagen General Popu-
lation study cohort (𝑛 = 94,079) assessed prospectively the
risk of asthma and CVD including ischemic heart disease,
myocardial infarction, and ischemic stroke among smokers
and nonsmokers. Six percent (𝑛 = 5691) had self-reported
asthma, 40% were never smokers, 43% former smokers, and
16% current smokers. Mean follow-up time of the study
patients (age 20–100 years) was 4.5 years. Hazard ratios
among individuals with asthma compared to never smokers
without asthma for ischemic heart disease were 1.5 in former
smokers and 2.0 in current smokers. The respective corre-
sponding values were 1.7 and 3.2 for myocardial infarction
and 1.2 (n.s.) and 3.0 for ischemic stroke. In contrast to
previous studies the increased risk for cardiovascular comor-
bidities in this cohort study was restricted only to smokers
with asthma [96]. Unfortunately data on the age at asthma
onset was not available as in other cohorts the increased risk
of CVD was seen mostly only in women with adult-onset
asthma. In addition, the follow-up time (4.5 years) is relatively
short for the never smoker asthma group as they were women
with a mean age of 53. The risk of myocardial infarction in
smoking persons increases more early but in never smokers
(especially women) it clearly increases only after the age of 60
[97]. In most asthma comorbidity studies confounding effect
of smoking has been taken into account. Usually patients have
been divided into groups of current, ever, and never smokers.
In some studies data on pack-years is available. However,
more detailed information like duration, intensity, and type
of smoking as well as age of smoking onset and second hand
smoking should be part of the multivariate models especially
in studies concerning asthma and the risk of cardiovascular
diseases [98].
These cross-sectional and cohort studies with large pop-
ulations have shown that asthma patients and especially a
subgroup of adult-onset asthma women are at increased risk
of arteriosclerosis. In future, it would be important to know
whether totally controlled asthma would reduce the risk
of cardiovascular comorbidities. The role of contemporary
asthma medication to prevent or to enhance incidence of
cardiovascular diseases also remains obscure. Furthermore,
we lack knowledge of how different CVDs affect asthma
outcome and whether CVDs are of importance in making
decisions on how to modify treatment of asthma.
7. Mental Disorders, Suicide, and Asthma
The association between asthma and psychological factors
has been recognized for centuries [99]. Psychosocial factors
have long been suspected to influence the onset and course of
asthma. These effects may be mediated via direct influences
such as influences on the pulmonary system, autonomic
and endocrine regulation, and inflammatory and immune
process (see later in this paper and [100]). In addition, psy-
chosocial factors can influence asthma via multiple indirect
pathways such as medication adherence, perception of air-
way obstruction (either overperception or underperception),
illness beliefs, or general health behavior [100].
A considerable number of studies have suggested that
there is an association between some mental disorders and
asthma, especially severe asthma [99–101]. Studies conducted
among clinical and general practice samples have found
higher than expected rates of anxiety disorders (particularly
panic disorder) and of depression among adult patients with
asthma [99]. However, the published results have not always
been consistent andmethodological problems (e.g., not using
DSM-based diagnostics and variability in the assessment of
asthma) make it difficult to draw clear conclusions [99, 100].
7.1. Is There Association between Asthma and Mental Dis-
orders? The World Mental Health Survey performed in 17
countries (𝑛 = 85,088) using general population sample
reports that an adult with asthma has an increased risk for
depressive disorders (OR 1.6) and anxiety disorder (OR 1.5)
as compared with persons not having asthma [101]. A meta-
analysis estimating the prevalence of anxiety disorders in
asthma reported that the average prevalence of any anxiety
disorder among adults with asthma was 34% [102]. More
specifically, the prevalence of panic attacks (25%), panic
disorder (12%), agoraphobia (12%), and generalized anxiety
disorder (9%) was higher among adults with asthma than in
the general population [102]. A recentmeta-analysis has eval-
uated the association between asthma and depression [103].
Patients with depression had increased risk for having asthma
(OR 3.2) as compared with those not having depression and
patients with asthma had an increased risk for having depres-
sion (OR 1.5) as compared with those not having asthma
[103]. A similar association has been reported from Span-
ish National Health Survey [104] reporting that asthmatic
patients suffermore often from anxiety (9.7%) and depression
(9%) than persons not having asthma (6.6% and 5.5% for
anxiety and depression, resp.). Having asthma increased the
probability of suffering from anxiety (OR 1.3) and depression
(OR 1.4). Among asthmatics factors associated with suffering
from anxiety were older age, concomitant comorbidities, and
visits to GP practices in the last 4 weeks, whereas factors
associated with depression were female sex, older age, worse
self-related health, concomitant comorbidities, abstemious
individuals, and the need for attendance on emergency room
in the last year [104]. A similar association has been reported
also fromGermany reporting that lifetime severe asthma was
significantly associated with an increased risk for a number
of anxiety disorders (any anxiety disorder, panic disorder,
panic attacks, social phobia, specific phobia, and generalized
anxiety disorder), bipolar disorder, and any severe mental
disorder [105]. Lifetime nonsevere asthma was significantly
associated with having any anxiety disorder, not specified
anxiety disorder, and with any somatoform disorder [105].
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It appears that the association between anxiety/depression
and asthma is not limited to Western countries as similar
association has been reported fromChinese population [106]
and from an analysis of self-reported data from most of
the evaluated 54 countries [107]. In addition, the association
between asthma and/or atopic diseases with anxiety and
depression is not limited to adults only but has been reported
also in children [108] and adolescents [109].
In a Norwegian population-based survey [110] cases with
a personality problem evaluated using the Iowa Personality
Disorder Screenmore frequently reported asthma along with
other chronic conditions such as persistent muscular pain,
fibromyalgia, and alcohol problems. Asthma (ever suffered
from asthma) was found to be of borderline significance in
influencing the prevalence of personality problems [110]. As
patients with personality problems have increased somatic
morbidity and primary health care utilization these results
raise another possible cluster of diseases, namely, association
between asthma and personality problems and persistent
musculoskeletal pain and fibromyalgia that are generally
considered as “noninflammatory” diseases. A possible link
between these conditions and asthma may be the increased
use of nonprescribed analgesics by these patients.
Suicide is a major public health issue worldwide often
associated with mental illnesses. Asthma can have a signifi-
cant effect on quality of life, and consequences include sleep-
lessness, daytime fatigue, reduced activity levels, school and
work absenteeism, and mental health problems [111]. Thus,
it can be hypothesized that asthma could be associated with
suicide-related behavior. A recent review [111] collected the
available observational studies between asthma and suicide-
related behavior (ideation, attempts, and completion). The
evidence from six different observational studies support an
association between asthma and suicide-related behavior the
risk being 1.4–3.5 times higher in patients with asthma as
compared with nonasthmatic counterparts [111].
7.2. Does Asthma Predispose to Mental Disorders? The only
study identified to address this connection evaluated whether
asthma predisposes to mental disorders in a longitudinal
setting in a Danish birth cohort (children born between
1977 and 1992 and followed up from the age of 15 until
year 2008) when they were evaluated for the presence of
schizophrenia [112]. Asthmawas associatedwith an increased
risk (RR 1.6) for developing schizophrenia and the risk was
confirmed in a case/sibling study [112]. Due to its setting (free
of chargeDanish public health care), this studymost probably
avoids most of the biases usually related to studies on mental
disorders. However, it evaluates only hospital discharge and
outpatient data and may thus exclude the less severe cases of
asthma.
7.3. Do Mental Disorders Predispose to Asthma? As a part of
World Mental Health surveys (𝑛 = 18,303) the association
between childhood adversities (physical abuse, sexual abuse,
neglect, parental death, parents divorce, another parental loss,
parental mental disorder, parental substance use, parental
criminal behavior, family violence, and family economic
adversity) and early-onset depressive and anxiety disorders
and adult-onset asthma has been evaluated [113]. Childhood
adversities predicted adult-onset asthma with risk increasing
with the number of adversities experienced (HRs 1.5–1.7).
However, also early-onset depressive and anxiety disorders
independently predicted adult-onset asthma (HRs 1.7–2.1).
This suggests that mental disorder-asthma relationship is
independent and not a function of a shared background
of childhood adversity [113]. Data collected from face-to-
face household surveys in community-dwelling adults (𝑛 =
52,095) from 19 countries evaluated the lifetime prevalence
and age at onset of 16DSM-IVmental disorders aswell as self-
reported physician diagnosis of asthma and age at onset. After
adjustment for comorbid mental disorders several mental
disorders were associated with subsequent adult asthma
onset: bipolar disorder (OR 1.8), panic (OR 1.4), generalized
anxiety (OR 1.3), specific phobia (OR 1.3), posttraumatic
stress (OR 1.5), binge eating (OR 1.8), and alcohol abuse (OR
1.5). Mental comorbidity linearly increased the association
with adult asthma. The association with subsequent asthma
was stronger formental disorders with early onset (before age
of 21) [114]. The major biases in these multinational analyses
may relate to cultural differences in the diagnostic accuracy
when questions on doctor-diagnosed asthma are presented or
the World Mental Health survey tools are used.
7.4. Do the Mental Disorders Affect Clinical Asthma? Anxiety
and other psychiatric morbidities are often advised to be
considered in differential diagnostic and when estimating
treatment options in severe asthma or asthma not responding
to treatment. Despite this common advice there exist rela-
tively few studies that have directly evaluated how the mental
disorders affect clinical asthma. The effects of comorbid
mental disorders on health care service use and psychosocial
factors in asthma have been reviewed recently [100, 115]. In
this review we included only studies more recently published
or most relevant to adult asthma. A clinical sample of adult
Canadian patients with asthma (𝑛 = 504, not specifically
adult-onset asthma) was subjected to evaluation of the
presence of depressive and/or anxiety disorders by using
the Primary Care Evaluation of Mental Disorders Interview
[116]. Almost one-third of the patients fulfilled the diagnostic
criteria for either condition (8% were depressive only and
12% had anxiety only) or both (11%) of these disorders.
Depressive disorder had an independent worsening effect
on asthma control, whereas both depressive and anxiety
disorder independently impaired asthma-related quality of
life [116]. In contrast, there were no significant differences
in other asthma-related endpoints (lung function, severity,
atopy, emergency department visits, hospitalization in the last
year, or asthma medication) [116]. The same research group
has more recently analysed the impact of generalized anxiety
disorder on asthma morbidity in a sample of adult patients
with confirmed asthma (𝑛 = 749, not specifically adult-
onset asthma) [107]. Generalized anxiety disorder affected
4% of the patients and impaired asthma control and asthma-
related quality of life, increased bronchodilator use, and was
associated with worse asthma self-efficacy [117]. However, the
comorbid major depressive disorder and low asthma self-
efficacy may account for many of these associations [117]. In
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contrast, there was no association between generalized anx-
iety disorder and emergency visits or hospitalizations [117].
This is in line with a systematic review made on psychiatric
morbidity and asthma and health care costs [115] in which
mood disorders (depression), posttraumatic stress disorder,
and not specified mental disorder were found to increase
the risk for emergency department visits (ORs 2.6, 5.2, and
4.6, resp.). In contrast, results for anxiety/panic disorder
were not consistent between studies [115], although they
suggest a trend towards increased emergency department
visits. Similarly, increased rate of general practitioner visits
was found with patients having depression, posttraumatic
stress disorder, and not specified mental disorder but the
results with anxiety/panic disorder were not consistent [115].
A recent analysis evaluated the effect of panic disorder
and panic-anxiety on asthma control, health service use,
and quality of life in adult patients with asthma (𝑛 =
643, not specifically adult-onset asthma) during a 4-year
follow-up [118]. Panic disorder and anxiety sensitivity index
(ASI) scores predicted worse follow-up ACQ total scores but
not AQLQ scores [118]. ASI scores also predicted greater
nocturnal and waking symptoms, activity limitations, and
bronchodilator use. In contrast, neither panic disorder nor
ASI scores were associated with hospitalisation, although ASI
score was marginally associated with an increased risk of
emergency department visits (RR 1.023) [118]. Among severe
asthmatics the presence of a psychiatric disorder has been
reported to increase the risk for frequent visits toGP (OR5.9),
frequent emergency visits (OR 5.3), frequent exacerbations
(OR 12.4), and frequent hospitalizations (OR 4.8) even
though these patients do not differ from those not presenting
with psychiatric disorder in demographic or objective dis-
ease characteristics [119]. There exists a possibility that the
deleterious effects of mood or anxiety disorders on asthma
control might be mediated via behavioural effects such as
tobacco smoking. A recent study [120] evaluated this and
found that current smoking, having an anxiety disorder, and
having a mood disorder are independently associated with
poorer asthma control. Recently, it has been proposed that the
depressive symptoms mediate the relationship between BMI
and worse asthma control [121] although this has not been
confirmed in another study [122].
Mental disorders are often associated with increased rate
of work absence. The results of two separate studies [35, 123]
suggest an increased rate of work absence in asthma with
comorbid depression (ORs 3.6–4.0). In a Finnish analysis of
public sector employees [35], the risk was especially high for
permanent work disability (HR 6.8) [35].
There remain a number of possible problems with the
studies evaluating the effects of comorbid mental disorders
on the outcome of clinical asthma. Firstly, many studies are
cross-sectional and long-term follow-up studies are lacking.
Secondly, many studies rely on self-reported data rather
than clinical assessment or collection of clinically proven
events from patient records. Thirdly, the patient population
in clinical studies often represents tertiary care; that is, the
group of patients with asthma is highly selected. Fourthly,
smoking and differential diagnostics towards COPD are not
taken into account. However, there exists enough evidence to
suggest that psychiatric comorbidities associate with asthma
and may negatively affect its outcome. Thus, long-term
follow-up studies evaluating the effects of different mental
comorbidities on asthma outcome are needed.
8. Mechanisms Linking Asthma with
Its Comorbidities
Considering the high coexistence of obesity, metabolic syn-
drome, type 2 diabetes, and depression with asthma, it is
not surprising to find many overlapping pathways in their
possible pathogenetic mechanisms. Other than traditional,
Th2-related mechanisms are likely to explain the coexis-
tence, because the current reports suggest no clear associ-
ation between BMI and eosinophilic airway inflammation
in asthma. To briefly review studies concerning airway
inflammation in obese asthma, no difference was found
in airway inflammation in morbidly obese subjects with
or without asthma [124]. Increase in bronchial submucosal
eosinophils, even though not in blood or sputum eosinophils,
was reported in severe obese asthmatics when compared to
leaner asthmatics [125]. Inverse or no relationship between
BMI and sputum/blood eosinophilia or FeNOhas commonly
been described in patients with asthma. Furthermore, no
consistent results exist on predominating neutrophilic airway
inflammation either [46, 126–128]. Thereby, it is likely that
the increased symptoms in obese patients with asthma are
not explained by increased airway inflammation. Next, we
will continue by describing the mechanisms that link the
pathogenesis of comorbid conditions such as obesity, type
2 diabetes, cardiovascular diseases, and depression with
asthma. Due to high degree of overlapping mechanisms,
the section is sectioned by mechanisms instead of separate
comorbid conditions.
8.1. Early Life Exposures. Early life exposures such as mater-
nal diet, maternal smoking, air pollution, and pregnancy
complications affect metabolic health of the offspring and the
risk of developing chronic disease later in life. For example,
maternal obesity has been associated with both increased risk
of insulin resistance and asthma of the offspring during child-
hood [129, 130]. Also low birthweight has been associated
with increased risk of having asthma, hypertension, diabetes,
or heart diseases by age of 50 years [131]. These risks may be
mediated by structural, metabolic, or epigenetic changes that
occur in foetus in response to adverse environment in utero
[132]. For example, epigenetic modifications such as DNA or
histone methylation and histone acetylation in foetal genes
important for lipid or carbohydrate metabolism or immune
system are likelymechanisms involved in explaining later risk
and higher occurrence of many metabolic and other chronic
diseases [133].
Severe early life stress has been associatedwith depression
as well as asthma later in life [134–137]. To explain this
association, severe childhood stress was shown to predispose
to persistently high inflammatory status of the body (CRP
and IL-6) lasting to adulthood. In subjects with severe
childhood adverse events the systemic levels of inflammatory
cytokines were also raised higher in response to an adverse
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event in adulthood when compared to those without child-
hood adverse events [134, 135]. The persistently activated
inflammatory pathways may increase susceptibility to other
chronic inflammatory diseases.
8.2. Systemic Inflammation. Systemic inflammation is a phe-
nomenon common for obesity, diabetes mellitus, depression,
and at least certain phenotypes of asthma constituting a
possible link between these disorders [103, 138]. Systemic
inflammation is generated by adipose tissue at the obese
state or can be developed, for example, in response to
severe social stress. It is characterized by increased levels
of inflammatory markers such as C-reactive protein (CRP),
interleukin- (IL-) 6, IL-1𝛽, tumor necrosis factor- (TNF-)
𝛼, and leptin. Elevated IL-6, CRP, and soluble CD163
(macrophage activation marker) have been associated with
reduced lung function (especially in severe asthma) and
neutrophilic airway inflammation [138–140]. TNF-𝛼 has
also been shown to enhance eosinophil survival [141]. IL-6
possesses wide effects on innate immune system and has been
proposed to play an active role in asthma pathogenesis. IL-6
may affect asthma development, for example, by stimulating
neutrophil recruitment and T helper cell differentiation into
Th2 or Th17 cells (the latter in the presence of TGF-𝛽) or by
stimulating IL-13 production by T helper cells [142, 143].Th17
cells are involved in neutrophil recruitment; they are steroid-
resistant (in contrast to, e.g., Th2 cells) and considered to be
significant players in severe neutrophilic asthma. Recently,
higher amount of dual-positive Th2/Th17 cells was found
from BAL of patients with refractory asthma when compared
to disease control subjects [144]. IL-6 and IL-1𝛽 are cytokines
able to induce differentiation of Th2 cells into Th2/Th17 cells
and are likely involved. Amount of Th2/Th17 cells as well
as IL-17 levels in these patients positively correlated with
airway hyperreactivity and eosinophil counts and negatively
correlated with FEV
1
suggesting thatTh2/Th17 cells associate
with severe asthma. Moreover, dual-positive Th2/Th17 cells
were resistant to proapoptotic effects of glucocorticoids [144].
Given that obese patients with asthma are less sensitive
to treatment with steroids [38] either Th2/Th17 or Th17
induction by IL-6 may play a significant role in the disease
process. Because obesity stimulates systemic inflammation,
and cytokines of systemic inflammation skew Th cells into
Th17, elevated levels of Th17 cells and elevated production of
IL-17 would also be expected in obese subjects and patients
with type 2 diabetes. Indeed, this was shown in peripheral
blood cells from patients with type 2 diabetes [145]. More-
over, 3–10-fold increases in Th17 cells were demonstrated in
adipose tissue from obese patients with insulin resistance,
when compared to obese insulin-sensitive or lean patients
[146]. Taken together,Th17 cells may be induced in themilieu
of systemic inflammation and play a role in pathogenesis of
both insulin resistance and asthma. Th17 cells have also been
shown to increase with age in healthy humans [147], and an
experimental study suggested that development of Th2/Th17
milieu following allergic response would be related to older
age [147, 148].
A recent study on gene expression of blood CD4+ T
cells from patients with depression and asthma showed
that the main active pathways in depressive asthma are
those related to acute phase protein signalling (such as IL-
6 and CRP signalling) [149]. Chronic stress may lead to
dysregulation of hypothalamic-pituitary-adrenal (HPA) axis,
long-term increase in the levels of cortisol, glucocorticoid
resistance, and systemic inflammation. Cytokines elevated
during systemic inflammation are able to generate symptoms
such as fatigue and loss of appetite that overlap with symp-
toms of depression [137, 150]. Moreover, reduced serotonin
neurotransmission is present in depression and inflamma-
tory cytokines elevate enzyme indoleamine-2,3-dioxygenase
(IDO), which degrades the most important precursor of
serotonin, tryptophan [151].
8.3. Inflammasome. Nod-like receptor protein 3 (NLRP3)
inflammasome is a multiprotein complex at the interface of
metabolism and inflammation and involved in the develop-
ment of systemic inflammation. Its activation is a two-step
process leading to release of IL-1𝛽 and IL-18, mainly in the
cells of innate immunity. The interest lies in its ability to
be activated by wide array of dangerous substances ranging
from pathogens to metabolic compounds (elevated extracel-
lular glucose, amyloid-𝛽 peptide, and oxidized low-density
lipoprotein (LDL)), extracellular acidosis, and number of
environmental irritants [152]. Also psychological stressors
have been shown to elevate IL-1𝛽 and may therefore activate
inflammasome, even though direct activation mechanisms
have not been demonstrated [153]. The precise mechanisms
of NLRP3 inflammasome activation by these various factors
are largely unknown. Extensive literature supports the role of
ROS and mitochondrial dysfunction in inflammasome acti-
vation, both being common in obesity, diabetes, and asthma
[152, 154]. Studies with knock-out mice have suggested that
under normal circumstances IL-1𝛽 is important for mainte-
nance of adipose tissue homeostasis and has partially over-
lapping functions with IL-6. However, during inflammatory
conditions and chronic stimulation, it drives obesity-related
disease progression, for example, by interfering with insulin
signalling in adipose tissue and liver. Interestingly, inmice IL-
1𝛽 and TNF-𝛼 also upregulated serotonin transporter (SERT)
gene that is central in inducing despair-like behaviour by
uptake of serotonin to the presynaptic neuron [155, 156]. By
thismechanism inflammasome and IL-1𝛽 could contribute to
depression.Moreover, NLRP3 inflammasome has been found
to be involved in ageing-related inflammation and cognitive
decline [152].
Finally, development of airway hyperresponsiveness in
response to high-fat diet in mice was shown to be dependent
on NLRP3 inflammasome-mediated production of IL-1𝛽 and
IL-17 [157]. IL-1𝛽 expanded IL-17A-producing type 3 innate
lymphoid cells (ILC3s) in the lungs. Also patients with severe
asthma were shown to have higher numbers of IL-17A-
positive ILC3-like cells in BAL when compared to healthy
subjects or patients with mild asthma [157]. Altogether,
existence of wide array of activators of NLRP3 inflammasome
suggests that it may be involved in translating metabolic or
inflammatory danger signals into metabolic diseases, airway
hyperresponsiveness, and even depression.
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8.4. Adipokines. Adipokines have been widely studied in the
context of finding the link between obesity and asthma.
Adipokines are group of cytokines produced by adipose
tissue and contain mediators with proinflammatory (e.g.,
leptin and resistin) and anti-inflammatory (e.g., adiponectin)
functions. Serum levels of leptin increase with increasing
BMI [158, 159] and are higher in females [160]. Both clinical
and experimental evidence suggest that leptin functions by
augmenting airway hyperresponsiveness but not by affecting
inflammation [161–163]. In obese patients with adult-onset
asthma, markers of metabolic inflammation, macrophage
number, and leptin levels were increased in visceral fat when
compared to obese controls and airway reactivity was sig-
nificantly correlated to visceral fat leptin expression [161]. In
nonobese women with adult-onset asthma, leptin correlated
negatively with lung function and positively with asthma
symptom score, after adjusting for BMI [164]. Howmetabolic
inflammation in visceral fat and themediators involved trans-
lates into airway hyperresponsiveness remains unknown.
Adipokine receptors are expressed in the airway epithelium
and smooth muscle cells and in eosinophils suggesting that
there may be direct effects on the structural and inflam-
matory cells of the airways [161, 165, 166]. In eosinophils,
leptin has been shown to promote survival [167, 168].
Adiponectin is an adipokine with insulin-sensitizing and
anti-inflammatory effects, and low level of adiponectin has
been associated with both incident asthma and metabolic
disorders, even though the association has not been con-
sistent [169, 170]. Currently, the primary target cells that
are important for the beneficial anti-inflammatory effects
of adiponectin are unknown. Adiponectin circulates in the
blood only in multimeric forms with low, medium, or high
molecular weights and their distribution differs in men and
women [171]. Indeed, quite differential associations have been
found between adiponectin levels and metabolic diseases or
asthma in men and women, and the mechanisms may be
largely gender-specific [172, 173]. Even though adiponectin
has been demonstrated to suppress activation of many proin-
flammatorymolecules in adipocytes andmacrophages in pre-
vious studies [174, 175], very recently the effect of adiponectin
on inflammation was shown to be dependent onmacrophage
phenotype. In classically activated mouse M1 macrophages
adiponectin increased levels of proinflammatory cytokines
IL-6, TNF-𝛼, and IL-12 but in alternatively activated M2
macrophages it enhanced production of anti-inflammatory
IL-10 [176]. Even though M2 macrophages are prevalent in
traditional allergic asthma, obesity is associated with increase
in M1 macrophages at least in adipose tissue [177], and
thereby adiponectin might actually exert proinflammatory
effects in obesity-associated conditions. More studies are
needed to clarify the issue.
8.5. Hyperglycemia and Hyperinsulinemia. Studies have
shown 3–10% lower lung function (more consistently FVC
than FEV
1
) in adults with diabetes (without asthma) when
compared to adults without diabetes and the association
was independent from obesity or smoking. In longitudinal
studies, reduced baseline lung function (mostly FVC) was
also shown to predict incident diabetes [178]. Hyperglycemia
and hyperinsulinemia follow insulin resistance and are both
prevalent in metabolic syndrome and, in untreated type 2
diabetes, hyperinsulinemia is also present in treated type
2 diabetes. The effects of high glucose or insulin on the
lungs have received interest in attempts trying to find an
explanation to the association between diabetes and reduced
lung function.
Experimental studies and development of inhalation
formula of insulin have provided some interesting insights
to the direct effects of glucose and insulin on the lungs. In
experimental studies, insulin has been shown to contribute
to formation of hypercontractile airway smooth muscle cells
by promoting expression of laminin [179]. To support this,
inhalation of insulin by diabetic patients resulted in cough
and decrease in FEV
1
[180]. Insulin also promotes fibroblast
proliferation and differentiation resulting in collagen depo-
sition, thereby contributing to airway remodelling [181, 182].
However, infusion of insulin into obese subjects led to anti-
inflammatory effects in their peripheral blood mononuclear
cells. Insulin reduced short-term activation of NF-𝜅B and
expression of many inflammatory mediators (IL-4, ADAM-
33, LIGHT, and LTBR) related to asthma in these cells [183,
184]. In experimental studies, insulin has also contributed to
Th2 response and induced mast cell survival and degranula-
tion [181, 182]. In vitro, high glucose concentrationwas shown
to enhance responsiveness of airway smooth muscle cells
to contractile agents and to enhance intracellular calcium
release [185]. Altogether, chronically high insulin or glucose
levels in the lungs may promote airway hyperresponsiveness
and airway remodelling and thereby contribute to reduced
lung function or incident asthma in patients with diabetes.
Other mechanisms proposing to explain the reduced lung
function in patients with diabetes are microangiopathy of
the alveolar capillaries and pulmonary arterioles, as well as
autonomic neuropathy [178, 186].
Hyperglycemic condition is common in patients with
acute asthma exacerbations, and generally disturbance in
glucose metabolism has been described in patients with
asthma, even in the absence of any diabetic risk factors [187,
188]. Hyperglycemic condition may result from treatment
with systemic steroids and/or 𝛽
2
-agonists [187, 189]. Gluco-
corticoids promote gluconeogenesis in liver and antagonize
insulin response in skeletal muscle and adipose tissue leading
to hyperglycemia. However, treatment with inhaled steroids
seems not to predispose for insulin resistance or diabetes
[190].
8.6. Lung Mechanics. Obesity underlies many chronic con-
ditions and its direct effects on lung mechanics may also
contribute to development of asthma in these conditions. In
obese subjects, the increased soft tissue compresses the tho-
racic cage leading to higher frequency of breathing, reduced
peripheral airway diameter, and reduced lung volumes,which
may lead to dyspnoea [37]. Recently it was shown that obesity
is associated with increased resistance and dysfunction in
peripheral airways [191]. However, something must exist to
separate those obese subjects who develop asthma from
those who do not. A weight loss study in obese nonallergic
female asthmatics suggested that peripheral lung of the
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obese patients developing asthma may be more collapsible
when compared to obese controls [192]. Natural variation
in the airway wall stiffness and thickness could provide
explanation for the collapsibility and explain why some obese
individuals are prone to develop hyperresponsiveness and
asthma, and others are not. The airway wall properties could
be determined by genetics or be a result of obesity-related
altered metabolism [193].
8.7. Mitochondrial Dysfunction. Mitochondrial dysfunction
has been suggested as a common pathogenetic mechanism of
obesity, metabolic syndrome, and asthma [194]. Mitochon-
drial dysfunction and higher level of oxidative damage in
mitochondria has also been described in patients with major
depressive disorder (MDD) [195, 196]. In obese subjects,
caloric excess overloads mitochondria, leading to overpro-
duction of reactive oxygen species, damage to mitochondrial
(and cellular) components, and mitochondrial loss. Mito-
chondrial dysfunction results in incomplete oxidation of fatty
acids and increased circulating lipids. Some metabolically
active lipids inhibit insulin signalling and may promote
insulin resistance. The situation is aggravated by physical
inactivity, since physical activity is a way of increasing
mitochondrial activity [194, 197]. Similar changes in mito-
chondrial function occur in older age [198]. Mitochondrial
dysfunction has also been shown in experimental allergic
asthma in mice [199, 200] but evidence in human asthma
is limited to genetic studies [194]. Asthma is, however,
associated with oxidative stress [201], which may be partially
derived from dysfunction of mitochondria but also acceler-
ates mitochondrial dysfunction.
8.8. Disturbed Nitric Oxide Metabolism. Disturbed nitric
oxide metabolism is also common for asthma and metabolic
disorders. Obesity, metabolic syndrome, depression, cardio-
vascular diseases, and asthma have all been associated with
increased level of asymmetric dimethyl arginine (ADMA)
which is an inhibitor of all nitric oxide synthase (NOS)
isoforms [202–206]. In obese patients with asthma, decreased
ratio of L-arginine/ADMA in plasma and its association with
worse outcome of asthma were shown [207]. Endothelial
NOS is critical for vasodilatation, and its inhibition byADMA
may also lead to endothelial dysfunction, increased risk for
atherosclerosis, and other cardiovascular diseases [208]. In
airway diseases, the adverse effect of ADMA is thought to
be mediated by enhancement of oxidative stress, which was
shown in murine lung epithelial cells and in allergically
inflamed lungs of mice after administration of ADMA [209,
210]. Increased ADMA may direct NOS to form superoxide
instead of NO and lead to oxidative stress, mitochondrial
damage, and dysfunction.Mitochondrial dysfunction in turn
contributes to insulin resistance and type 2 diabetes by the
route described above. The NOS enzyme(s) most critical for
these effects remain to be determined. Another mechanism
that may affect development of asthma in response to NOS
inhibition is increased availability of L-arginine, the start-
ing substance of NO to arginase-1/arginase-2 resulting in
increased production of polyamines and proline. Polyamines
function by increasing airway hyperresponsiveness and
eosinophil survival and proline is precursor of collagen,
important for airway remodelling [211, 212]. Upregulated
arginase-1 has also been demonstrated in patients with dia-
betes and in patients with heart failure [213, 214], postulating
another common disease mechanism with asthma.
8.9. Leukotrienes. Leukotrienes construct another link
between asthma and cardiovascular diseases. In asthma,
cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are
well-known mediators of bronchoconstriction, mucus
production, and inflammatory cell recruitment in the
airways and produced mainly by eosinophils and mast cells.
Leukotrienes are derived from activation of 5-lipoxygenase
(5-LO). 5-LO is upregulated also in atherosclerotic lesions
and the increased number of 5-LO+ cells was described
during progression of coronary heart disease [215].
Additionally, higher count of 5-LO+ cells was found in
atherosclerotic plaque samples from symptomatic versus
asymptomatic patients with internal carotid artery stenosis.
Plaque samples from these symptomatic patients showed also
higher levels of LTB4 and active matrix metalloproteinases
(MMP) 2 and 9 [216]. MMPs contribute to myocardial
infarction by rupturing atherosclerotic plaques. Male
hormones showed suppressive effects on 5-LO products
[217] whereas estradiol stimulated release of cysteinyl
leukotriene C
4
frommast cells in vitro [218].These hormonal
influences might partly explain the stronger association
between cardiovascular diseases and asthma in women when
compared to men.
9. Conclusions and Future Perspectives
Studies concentrating on evaluating the risk factors of
asthma, impact on clinical disease, or impact on prognosis
give clearly different benefits for the clinician. If a comorbid
condition is a risk factor for asthma, it means that a person
having the comorbid condition (e.g., being obese) but not
having asthma has a higher probability of becoming asth-
matic at some point later in his/her life. This data can help
us guide, for example, the obese patient to lose weight and
thereby reduce the future risk of becoming asthmatic. In
addition, this knowledge can help us to target the preventive
measures at population level to reduce the risk of developing
a certain disease. However, to help the clinician to decide how
to treat the patient we need to know what is the significance
of the particular comorbidity for asthma control, severity,
and lung function and how it affects therapy. To understand
this we need clinical studies that evaluate the effect of the
comorbidity on asthma disease activity and outcomes in
asthma.
The mechanisms dealt in this review mainly originate
from patient and experimental data measuring the differ-
ent pathophysiological events, cells, and cell functions and
possible mediators that might be relevant in the interac-
tion between the particular comorbidity and asthma. Thus,
these mechanisms rather represent the situation where the
comorbid condition is affecting the clinical outcome of
asthma. Instead, theymaynot prove that a certainmechanism
or mediator is causative or mediating the development
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of asthma. That kind of study would require a different
experimental setting. For example, measurement of certain
mediators in large population samples and following whether
these people later develop incident asthma or not might help
to resolve those questions.
For comorbidities such as MBO or its components, DM2
and CVD, we lack studies that evaluate their effect on
clinical asthma. There exists some preliminary evidence on
the deleterious effects of obesity and mental disorders on
asthma outcome (Figure 1). Clinical studies that evaluate
long-term prognosis and the contribution of obesity (or other
comorbidities) on asthma are needed. In addition, studies
that evaluate changes in the comorbidity over time on asthma
control, exacerbations, lung function, and drug usage are
lacking. Obesity has been in focus during last years. However,
obesity itself is associated with significant comorbidity (such
as diabetes, cardiovascular diseases, andmental diseases) and
lifestyle factors (such as smoking, unhealthy diet, chronic
alcohol use, and low level of physical exercise) that may
contribute to the asthma outcome. From the mechanistic
point of view it may be rational to include patients with only
single comorbidity (e.g., obesity) to asthma studies at the
time (see, e.g., Table 1(a)). However, from the perspective
of practicing respiratory specialist or general physician this
is not optimal as most patients suffer from multimorbidity
rather than from a single disease or a combination of two
specific single diseases. For example, in Germany most
patients (approximately 60%) have one or more diseases out
of eight listed in addition to asthma [34]. In Scotland with a
sample of almost 1.8million people of all ages,multimorbidity
affects one in four people [10]. Multimorbidity is oftenmet in
chronic diseases and in the elderly population [12]. Studies
in patients with asthma that do not exclude patients because
of comorbidities are thus warranted. Studies such as the
Seina¨joki Adult Asthma Study (SAAS) that evaluate the long-
term prognosis of new-onset asthma diagnosed at adult age
and excludes only childhood-onset patientsmay shed light on
this matter [219].
Many of the comorbidities associated with asthma occur
as cluster of diseases rather than as a single combination of
asthma with a specific comorbidity. As many of the suggested
mediators are common to these diseases, we propose that
there may not be a single mechanism for interaction between
asthma and certain comorbidity and another separate mech-
anism for the interaction between asthma and second comor-
bidity, and so forth. Instead, we think that there exists a group
of mechanisms that link with each other and most link with
obesity and/or components of metabolic syndrome. Table 2
presents an overview of proposed mechanisms between
asthma and certain comorbidities. Several mediators (e.g.,
IL-6 and ADMA) are associated with asthma and several
comorbidities ranging from obesity to cardiovascular and
psychiatric ones, suggesting that in addition to disease-
specific mediators there may be mediators that drive the
systemic inflammation playing a major role in the cluster of
diseases around asthma.
These comorbidities may have commonmechanisms and
mediators. There exist some data that obesity and mental
diseases may complicate asthma outcome, whereas data is
lacking on the effects of metabolic syndrome, diabetes, and
cardiovascular diseases on the outcomes of clinical asthma.
Competing Interests
The authors declare that they have no competing interests.
References
[1] T. To, S. Stanojevic, G. Moores et al., “Global asthma prevalence
in adults: findings from the cross-sectional world health survey,”
BMC Public Health, vol. 12, article 204, 2012.
[2] S. B. de Nijs, L. N. Venekamp, and E. H. Bel, “Adult-onset
asthma: is it really different?” European Respiratory Review, vol.
22, no. 127, pp. 44–52, 2013.
[3] S. E.Wenzel, “Asthmaphenotypes: the evolution fromclinical to
molecular approaches,” Nature Medicine, vol. 18, no. 5, pp. 716–
725, 2012.
[4] P. Ilmarinen, L. E. Tuomisto, and H. Kankaanranta, “Pheno-
types, risk factors, and mechanisms of adult-onset asthma,”
Mediators of Inflammation, vol. 2015, Article ID 514868, 19
pages, 2015.
[5] H. Bisgaard and K. Bonnelykke, “Long-term studies of the
natural history of asthma in childhood,” Journal of Allergy and
Clinical Immunology, vol. 126, no. 2, pp. 187–197, 2010.
[6] E. Ro¨nmark, A. Lindberg, L. Watson, and B. Lundba¨ck, “Out-
come and severity of adult onset asthma—report from the
obstructive lung disease in northern Sweden studies (OLIN),”
Respiratory Medicine, vol. 101, no. 11, pp. 2370–2377, 2007.
[7] L. E. Tuomisto, P. Ilmarinen, and H. Kankaanranta, “Prognosis
of new-onset asthma diagnosed at adult age,” Respiratory
Medicine, vol. 109, no. 8, pp. 944–954, 2015.
[8] A. Sood, C. Qualls, M. Schuyler et al., “Adult-onset asthma
becomes the dominant phenotype among women by age 40
years: the longitudinal CARDIA study,” Annals of the American
Thoracic Society, vol. 10, no. 3, pp. 188–197, 2013.
[9] C. C. Imes and L. E. Burke, “The obesity epidemic: the United
States as a cautionary tale for the rest of the world,” Current
Epidemiology Reports, vol. 1, no. 2, pp. 82–88, 2014.
[10] K. Barnett, S. W. Mercer, M. Norbury, G. Watt, S. Wyke, and B.
Guthrie, “Epidemiology of multimorbidity and implications for
health care, research, and medical education: a cross-sectional
study,”The Lancet, vol. 380, no. 9836, pp. 37–43, 2012.
[11] B. Pache, P. Vollenweider, G. Waeber, and P. Marques-Vidal,
“Prevalence of measured and reported multimorbidity in a
representative sample of the Swiss population,” BMC Public
Health, vol. 15, article 164, 2015.
[12] S.W.Mercer, “Comorbidity in asthma is important and requires
a generalist approach,”PrimaryCare Respiratory Journal, vol. 23,
no. 1, pp. 4–5, 2014.
[13] J. M. Spergel, “From atopic dermatitis to asthma: the atopic
march,”Annals of Allergy, Asthma and Immunology, vol. 105, no.
2, pp. 99–106, 2010.
[14] J. Bousquet, J. M. Anto, P. Demoly et al., “Severe chronic allergic
(and related) diseases: a uniform approach—a MeDALL—
GA2LEN—ARIA position paper,” International Archives of
Allergy and Immunology, vol. 158, no. 3, pp. 216–231, 2012.
[15] C. A. Akdis, C. Bachert, C. Cingi et al., “Endotypes and pheno-
types of chronic rhinosinusitis: a PRACTALL document of the
European Academy of Allergy and Clinical Immunology and
Mediators of Inflammation 17
the American Academy of Allergy, Asthma & Immunology,”
Journal of Allergy and Clinical Immunology, vol. 131, no. 6, pp.
1479–1490, 2013.
[16] L. F. Eichenfield, W. L. Tom, S. L. Chamlin et al., “Guidelines of
care for themanagement of atopic dermatitis: section 1. Diagno-
sis and assessment of atopic dermatitis,” Journal of the American
Academy of Dermatology, vol. 70, no. 2, pp. 338–351, 2014.
[17] D. P. Guh, W. Zhang, N. Bansback, Z. Amarsi, C. L. Birming-
ham, andA.H.Anis, “The incidence of co-morbidities related to
obesity and overweight: a systematic review andmeta-analysis,”
BMC Public Health, vol. 9, article 88, 2009.
[18] L.-P. Boulet and M.-E`. Boulay, “Asthma-related comorbidities,”
Expert Review of RespiratoryMedicine, vol. 5, no. 3, pp. 377–393,
2011.
[19] D. K. Ledford and R. F. Lockey, “Asthma and comorbidities,”
Current Opinion in Allergy and Clinical Immunology, vol. 13, no.
1, pp. 78–86, 2013.
[20] M.Cazzola, A. Segreti, L. Calzetta, and P. Rogliani, “Comorbidi-
ties of asthma: current knowledge and future research needs,”
Current Opinion in Pulmonary Medicine, vol. 19, no. 1, pp. 36–
41, 2013.
[21] P. Kauppi, H. Kupiainen, A. Lindqvist et al., “Overlap syndrome
of asthma and COPD predicts low quality of life,” Journal of
Asthma, vol. 48, no. 3, pp. 279–285, 2011.
[22] Global Initiative for Asthma, Global Strategy for Asthma Man-
agement and Prevention, 2014, http://www.ginasthma.org.
[23] Global Strategy for the Diagnosis, Management and Prevention
of COPD, Global Initiative for Chronic Obstructive Lung
Disease (GOLD) 2014, http://www.goldcopd.org/.
[24] M. Miravitlles, J. J. Soler-Catalun˜a, M. Calle et al., “Guı´a
Espan˜ola de la EPOC (GesEPOC). Tratamiento farmacolo´gico
de la EPOC estable,” Archivos de Bronconeumologı´a, vol. 48, no.
7, pp. 247–257, 2012.
[25] H.Kankaanranta, T.Harju,M.Kilpela¨inen et al., “Diagnosis and
pharmacotherapy of stable chronic obstructive pulmonary dis-
ease: the finnish guidelines,” Basic & Clinical Pharmacology and
Toxicology, vol. 116, no. 4, pp. 291–307, 2015.
[26] M. Miravitlles, J. J. Soler-Catalun˜a, M. Calle et al., “A new
approach to grading and treating COPD based on clinical
phenotypes: summary of the Spanish COPD guidelines (GesE-
POC),” Primary Care Respiratory Journal, vol. 22, no. 1, pp. 117–
121, 2013.
[27] Ø. Karlstad, P. Nafstad, A. Tverdal, S. Skurtveit, and K. Furu,
“Comorbidities in an asthma population 8–29 years old: a study
from theNorwegian PrescriptionDatabase,” Pharmacoepidemi-
ology and Drug Safety, vol. 21, no. 10, pp. 1045–1052, 2012.
[28] A. S. Gershon, C. Wang, J. Guan, and T. To, “Burden of comor-
bidity in individuals with asthma,” Thorax, vol. 65, no. 7, pp.
612–618, 2010.
[29] A. S. Gershon, J. Guan, C. Wang, J. C. Victor, and T. To,
“Describing and quantifying asthma comorbidty: a population
study,” PLoS ONE, vol. 7, no. 5, Article ID e34967, 2012.
[30] J. B. Soriano, G. T. Visick, H.Muellerova, N. Payvandi, and A. L.
Hansell, “Patterns of comorbidities in newly diagnosed COPD
and asthma in primary care,” Chest, vol. 128, no. 4, pp. 2099–
2107, 2005.
[31] H. Kankaanranta, A. Lahdensuo, E. Moilanen, and P. J. Barnes,
“Add-on therapy options in asthma not adequately controlled
by inhaled corticosteroids: a comprehensive review,”Respiratory
Research, vol. 5, article 17, 2004.
[32] S. Suissa, A. Kezouh, and P. Ernst, “Inhaled corticosteroids and
risks of diabetes onset and progression,” American Journal of
Medicine, vol. 123, no. 11, pp. 1001–1006, 2010.
[33] K. Mattishent, M. Thavarajah, P. Blanco, D. Gilbert, A. M.
Wilson, and Y. K. Loke, “Meta-review: adverse effects of inhaled
corticosteroids relevant to older patients,” Drugs, vol. 74, no. 5,
pp. 539–547, 2014.
[34] H. Steppuhn, U. Langen, T. Keil, and C. Scheidt-Nave, “Chronic
disease co-morbidity of asthma and unscheduled asthma care
among adults: results of the national telephone health interview
survey German health update (GEDA) 2009 and 2010,” Primary
Care Respiratory Journal, vol. 23, no. 1, pp. 22–29, 2014.
[35] R. Hakola, P. Kauppi, T. Leino et al., “Persistent asthma, comor-
bid conditions and the risk of work disability: a prospective
cohort study,” Allergy, vol. 66, no. 12, pp. 1598–1603, 2011.
[36] D. Gibeon, K. Batuwita, M. Osmond et al., “Obesity-associated
severe asthma represents a distinct clinical phenotype. Analysis
of the british thoracic society difficult asthma registry patient
cohort according to BMI,” Chest, vol. 143, no. 2, pp. 406–414,
2013.
[37] Z. Ali and C. S. Ulrik, “Obesity and asthma: a coincidence or a
causal relationship? A systematic review,” Respiratory Medicine,
vol. 107, no. 9, pp. 1287–1300, 2013.
[38] P. Sivapalan, Z. Diamant, and C. S. Ulrik, “Obesity and asthma:
current knowledge and future needs,” Current Opinion in
Pulmonary Medicine, vol. 21, no. 1, pp. 80–85, 2014.
[39] L. Wang, K. Wang, X. Gao, T. K. Paul, J. Cai, and Y. Wang, “Sex
difference in the association between obesity and asthma inU.S.
adults: findings from a national study,” Respiratory Medicine,
vol. 109, no. 8, pp. 955–962, 2015.
[40] B. Brumpton, A. Langhammer, P. Romundstad, Y. Chen, andX.-
M.Mai, “General and abdominal obesity and incident asthma in
adults: the HUNT study,” European Respiratory Journal, vol. 41,
no. 2, pp. 323–329, 2013.
[41] N. Assad, C. Qualls, L. J. Smith et al., “Body mass index is
a stronger predictor than the metabolic syndrome for future
asthma in women. The longitudinal CARDIA study,” American
Journal of Respiratory and Critical Care Medicine, vol. 188, no. 3,
pp. 319–326, 2013.
[42] M. Ruotsalainen, V. Sidoroff, E. Piippo-Savolainen, M. K.
Hyva¨rinen, and M. Korppi, “Association between overweight
and asthma or allergy: results from a prospective 27-year post-
bronchiolitis follow-up,” Current Pediatric Research, vol. 16, no.
2, pp. 95–100, 2012.
[43] J. I. Peters, J. M. McKinney, B. Smith, P. Wood, E. Forkner, and
A. D. Galbreath, “Impact of obesity in asthma: evidence from a
large prospective disease management study,” Annals of Allergy,
Asthma and Immunology, vol. 106, no. 1, pp. 30–35, 2011.
[44] S. Pakhale, S. Doucette, K. Vandemheen et al., “A comparison of
obese and nonobese people with asthma: exploring an asthma-
obesity interaction,” Chest, vol. 137, no. 6, pp. 1316–1323, 2010.
[45] S. Scott, J. Currie, P. Albert, P. Calverley, and J. P. H. Wilding,
“Risk of misdiagnosis, health-related quality of life, and BMI
in patients who are overweight with doctor-diagnosed asthma,”
Chest, vol. 141, no. 3, pp. 616–624, 2012.
[46] A. Lessard, H. Turcotte, Y. Cormier, and L.-P. Boulet, “Obesity
and asthma: a specific phenotype?” Chest, vol. 134, no. 2, pp.
317–323, 2008.
[47] F. Holguin, E. R. Bleecker, W. W. Busse et al., “Obesity and
asthma: an association modified by age of asthma onset,”
Journal of Allergy and Clinical Immunology, vol. 127, no. 6, pp.
1486.e2–1493.e2, 2011.
18 Mediators of Inflammation
[48] D. Gibeon, K. Batuwita, M. Osmond et al., “Obesity-associated
severe asthma represents a distinct clinical phenotype analysis
of the british thoracic society diffi cult asthma registry patient
cohort according to BMI,” Chest, vol. 143, no. 2, pp. 406–414,
2013.
[49] A. Bruno, E. Pace, F. Cibella, and P. Chanez, “Body mass index
and comorbidities in adult severe asthmatics,” BioMed Research
International, vol. 2014, Article ID 607192, 7 pages, 2014.
[50] A. K. Ramasamy, N. Gupta, and R. Kumar, “Impact of obesity
on bronchial asthma in Indian population,” Lung India, vol. 31,
no. 2, pp. 121–126, 2014.
[51] G. Ciprandi, I. Schiavetti, R. B. Fontana, V. Sorbello, and F.
L. M. Ricciardolo, “Overweight and obesity as risk factors for
impaired lung function in patients with asthma: a real-life
experience,” Allergy and Asthma Proceedings, vol. 35, no. 4, pp.
e62–e71, 2014.
[52] B. Taylor, D. Mannino, C. Brown, D. Crocker, N. Twum-Baah,
and F. Holguin, “Body mass index and asthma severity in the
National Asthma Survey,”Thorax, vol. 63, no. 1, pp. 14–20, 2008.
[53] J. E. Cotes, D. J. Chinn, and J. W. Reed, “Body mass, fat
percentage, and fat free mass as reference variables for lung
function: effects on terms for age and sex,” Thorax, vol. 56, no.
11, pp. 839–844, 2001.
[54] M. S. Biring, M. I. Lewis, J. T. Liu, and Z. Mohsenifar, “Pul-
monary physiologic changes of morbid obesity,” The American
Journal of the Medical Sciences, vol. 318, no. 5, pp. 293–297, 1999.
[55] G. N. Bedell, W. R. Wilson, and P. M. Seebohm, “Pulmonary
function in obese persons,” Journal of Clinical Investigation, vol.
37, no. 7, pp. 1049–1060, 1958.
[56] M. Schatz, R. S. Zeiger, S. J. Yang et al., “Prospective study on
the relationship of obesity to asthma impairment and risk,”The
Journal of Allergy and Clinical Immunology: In Practice, vol. 3,
no. 4, pp. 560.e1–565.e1, 2015.
[57] B. Stenius-Aarniala, T. Poussa, J. Kvarnstro¨m, E.-L. Gro¨nlund,
M. Ylikahri, and P.Mustajoki, “Immediate and long term effects
of weight reduction in obese people with asthma: randomised
controlled study,” British Medical Journal, vol. 320, no. 7238, pp.
827–832, 2000.
[58] H. A. Scott, P. G. Gibson, M. L. Garg et al., “Dietary restriction
and exercise improve airway inflammation and clinical out-
comes in overweight and obese asthma: a randomized trial,”
Clinical and Experimental Allergy, vol. 43, no. 1, pp. 36–49, 2013.
[59] S. Pakhale, J. Baron, R. Dent, K. Vandemheen, and S. D. Aaron,
“Effects of weight loss on airway responsiveness in obese adults
with asthma. Does weight loss lead to reversibility of asthma?”
Chest, vol. 147, no. 6, pp. 1582–1590, 2015.
[60] L.-P. Boulet, H. Turcotte, J. Martin, and P. Poirier, “Effect of
bariatric surgery on airway response and lung function in obese
subjects with asthma,” Respiratory Medicine, vol. 106, no. 5, pp.
651–660, 2012.
[61] A. van Huisstede, A. Rudolphus, M. Castro Cabezas et al.,
“Effect of bariatric surgery on asthma control, lung function
and bronchial and systemic inflammation in morbidly obese
subjects with asthma,”Thorax, vol. 70, no. 7, pp. 659–667, 2015.
[62] A. E.Dixon, R. E. Pratley, P.M. Forgione et al., “Effects of obesity
and bariatric surgery on airway hyperresponsiveness, asthma
control and inflammation,” Journal of Allergy and Clinical
Immunology, vol. 128, no. 3, pp. 508–515, 2011.
[63] K.Hasegawa, Y. Tsugawa, Y. Chang, andC.A.Camargo, “Risk of
an asthma exacerbation after bariatric surgery in adults,” Journal
of Allergy and Clinical Immunology, vol. 136, no. 2, pp. 288–294,
2015.
[64] J. V. Garmendia, D. Moreno, A. H. Garc´ıa, and J. B. De Sanctis,
“Metabolic syndrome and asthma,”Recent Patents on Endocrine,
Metabolic & Immune Drug Discovery, vol. 8, no. 1, pp. 60–66,
2014.
[65] B.M. Brumpton, C. A. Camargo Jr., P. R. Romundstad, A. Lang-
hammer, Y. Chen, and X.-M. Mai, “Metabolic syndrome and
incidence of asthma in adults: the HUNT study,” European
Respiratory Journal, vol. 42, no. 6, pp. 1495–1502, 2013.
[66] E. J. Lee, K. H. In, E. S. Ha et al., “Asthma-like symptoms are
increased in the metabolic syndrome,” Journal of Asthma, vol.
46, no. 4, pp. 339–342, 2009.
[67] M. B. Fessler, “Next stop for HDL: the lung,” Clinical and
Experimental Allergy, vol. 42, no. 3, pp. 340–342, 2013.
[68] M.B. Fessler, “Revisiting ‘Good’ and ‘Bad’ cholesterol.Thebattle
over flow through arteries now shifts to flow through airways,”
American Journal of Respiratory and Critical Care Medicine, vol.
191, no. 9, pp. 969–970, 2015.
[69] P. L. Enright, B. J. Ward, R. P. Tracy, and E. C. Lasser, “Asthma
and its association with cardiovascular disease in the elderly.
The carciovascular health study research group,” Journal of
Asthma, vol. 33, no. 1, pp. 45–53, 1996.
[70] C. Picado, R. Deulofeu, R. Lleonart et al., “Lipid and protein
metabolism in asthma. Effects of diet and corticosteroid ther-
apy,” Allergy, vol. 54, no. 6, pp. 569–575, 1999.
[71] A.V. Barochia,M.Kaler, R.A.Cuento et al., “Serumapolipopro-
tein A-I and large high-density lipoprotein particles are posi-
tively correlated with FEV
1
in atopic asthma,”American Journal
of Respiratory andCritical CareMedicine, vol. 191, no. 9, pp. 990–
1000, 2015.
[72] S. Dogra, C. I. Ardern, and J. Baker, “The relationship between
age of asthma onset and cardiovascular disease in Canadians,”
Journal of Asthma, vol. 44, no. 10, pp. 849–854, 2007.
[73] T. Zhang, B. C. Carleton, R. J. Prosser, and A. M. Smith, “The
added burden of comorbidity in patients with asthma,” Journal
of Asthma, vol. 46, no. 10, pp. 1021–1026, 2009.
[74] D. A. Hickson, R. L. Wilhite, M. F. Petrini, W. B. White, and C.
Burchfiel, “Asthma and asthma severity among african ameri-
can adults in the Jackson Heart Study,” Journal of Asthma, vol.
46, no. 4, pp. 421–428, 2009.
[75] M. Johnson, J. Nriagu, A. Hammad, K. Savoie, and H. Jamil,
“Asthma, environmental risk factors, and hypertension among
Arab Americans in metro Detroit,” Journal of Immigrant and
Minority Health, vol. 12, no. 5, pp. 640–651, 2010.
[76] S. C. Christiansen, M. Schatz, S.-J. Yang, E. Ngor, W. Chen, and
B. L. Zuraw, “Hypertension and asthma: a comorbid relation-
ship,” Journal of Allergy andClinical Immunology in Practice, vol.
2, pp. S2213–2198, 2015, [Epub ahead of print].
[77] N. Nurminen, S. Oikarinen, and H. Hyo¨ty, “Virus infections as
potential targets of preventive treatments for type 1 diabetes,”
The Review of Diabetic Studies, vol. 9, no. 4, pp. 260–271, 2012.
[78] S. F. Ehrlich, C. P. Quesenberry Jr., S. K. Van Den Eeden, J.
Shan, and A. Ferrara, “Patients diagnosed with diabetes are at
increased risk for asthma, chronic obstructive pulmonary dis-
ease, pulmonary fibrosis, and pneumonia but not lung cancer,”
Diabetes Care, vol. 33, no. 1, pp. 55–60, 2010.
[79] S. F. Thomsen, D. L. Duffy, K. O. Kyvik, A. Skytthe, and V.
Backer, “Risk of asthma in adult twins with type 2 diabetes and
increased body mass index,” Allergy, vol. 66, no. 4, pp. 562–568,
2011.
[80] M. Hashemzadeh and M. R. Movahed, “The occurrence of
asthma in hospitalized patients with type 2 diabetes mellitus,”
Internal Medicine Journal, vol. 39, no. 10, pp. 699–701, 2009.
Mediators of Inflammation 19
[81] N. T. Mueller, W.-P. Koh, A. O. Odegaard, M. D. Gross, J.-M.
Yuan, andM. A. Pereira, “Asthma and the risk of type 2 diabetes
in the Singapore Chinese Health Study,” Diabetes Research and
Clinical Practice, vol. 99, no. 2, pp. 192–199, 2013.
[82] P. M. O’Byrne, S. Rennard, H. Gerstein et al., “Risk of new
onset diabetes mellitus in patients with asthma or COPD taking
inhaled corticosteroids,” Respiratory Medicine, vol. 106, no. 11,
pp. 1487–1493, 2012.
[83] J. S. Rana,M.A.Mittleman, J. Sheikh et al., “Chronic obstructive
pulmonary disease, asthma, and risk of type 2 diabetes in
women,” Diabetes Care, vol. 27, no. 10, pp. 2478–2484, 2004.
[84] Y. Song, A. Klevak, J. E. Manson, J. E. Buring, and S. Liu,
“Asthma, chronic obstructive pulmonary disease, and type 2
diabetes in the Women’s Health Study,” Diabetes Research and
Clinical Practice, vol. 90, no. 3, pp. 365–371, 2010.
[85] H. D. Yun, E. Knoebel, Y. Fenta et al., “Asthma and proinflam-
matory conditions: a population-based retrospective matched
cohort study,” Mayo Clinic Proceedings, vol. 87, no. 10, pp. 953–
960, 2012.
[86] K. Tore´n and N. B. Lindholm, “Do patients with severe asthma
run an increased risk from ischaemic heart disease?” Inter-
national Journal of Epidemiology, vol. 25, no. 3, pp. 617–620,
1996.
[87] V. Bellia, C. Pedone, F. Catalano et al., “Asthma in the elderly:
mortality rate and associated risk factors for mortality,” Chest,
vol. 132, no. 4, pp. 1175–1182, 2007.
[88] H. M. Lee, S. T. Truong, and N. D. Wong, “Association of
adult-onset asthma with specific cardiovascular conditions,”
Respiratory Medicine, vol. 106, no. 7, pp. 948–953, 2012.
[89] C. Iribarren, I. V. Tolstykh, and M. D. Eisner, “Are patients
with asthma at increased risk of coronary heart disease?” Inter-
national Journal of Epidemiology, vol. 33, no. 4, pp. 743–748,
2004.
[90] M. Szklo, R. Barnes, A. Folsom et al., “The atherosclerosis risk
in communities (ARIC) study: design and objectives,”American
Journal of Epidemiology, vol. 129, no. 4, pp. 687–702, 1989.
[91] J. G. Schanen, C. Iribarren, E. Shahar et al., “Asthma and
incident cardiovascular disease: the Atherosclerosis Risk in
Communities study,”Thorax, vol. 60, no. 8, pp. 633–638, 2005.
[92] S. Onufrak, J. Abramson, andV.Vaccarino, “Adult-onset asthma
is associated with increased carotid atherosclerosis among
women in the atherosclerosis risk in communities (ARIC)
study,” Atherosclerosis, vol. 195, no. 1, pp. 129–137, 2007.
[93] S. J. Onufrak, J. L. Abramson, H. D. Austin, F. Holguin, W. M.
McClellan, and L. V. Vaccarino, “Relation of adult-onset asthma
to coronary heart disease and stroke,” American Journal of
Cardiology, vol. 101, no. 9, pp. 1247–1252, 2008.
[94] C. Iribarren, I. V. Tolstykh, M. K. Miller, E. Sobel, and M.
D. Eisner, “Adult asthma and risk of coronary heart disease,
cerebrovascular disease, and heart failure: a prospective study
of 2 matched cohorts,” American Journal of Epidemiology, vol.
176, no. 11, pp. 1014–1024, 2012.
[95] M. C. Tattersall, M. Guo, C. E. Korcarz et al., “Asthma
predicts cardiovascular disease events: the multi-ethnic study
of atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 35, no. 6, pp. 1520–1525, 2015.
[96] Y. C¸olak, S. Afzal, B. G. Nordestgaard, and P. Lange, “Character-
istics and prognosis of never-smokers and smokers with asthma
in the copenhagen general population study. A prospective
cohort study,”American Journal of Respiratory and Critical Care
Medicine, vol. 192, no. 2, pp. 172–181, 2015.
[97] M. Pujades-Rodriquez, J. George, A. D. Shah et al., “Heteroge-
neous associations between smoking and a wide range of initial
presentations of cardiovascular disease in 1 937 360 people in
England: lifetime risks and implications for risk prediction,”
International Journal of Epidemiology, vol. 44, no. 1, pp. 129–141,
2015.
[98] J. Garcia-Aymerich, “The role of smoking in the association
between asthma and cardiovascular disease. An example of
poorly controlled confounding,” American Journal of Respira-
tory and Critical Care Medicine, vol. 192, no. 2, p. 123, 2015.
[99] M. Opolski and I. Wilson, “Asthma and depression: a prag-
matic review of the literature and recommendations for future
research,” Clinical Practice and Epidemiology in Mental Health,
vol. 1, article 18, 2005.
[100] T. Ritz, A. E. Meuret, A. F. Trueba, A. Fritzsche, and A. von
Leupoldt, “Psychosocial factors and behavioral medicine inter-
ventions in asthma,” Journal of Consulting and Clinical Psychol-
ogy, vol. 81, no. 2, pp. 231–250, 2013.
[101] K. M. Scott, M. Von Korff, J. Ormel et al., “Mental disorders
among adults with asthma: results from theworldmental health
Survey,” General Hospital Psychiatry, vol. 29, no. 2, pp. 123–133,
2007.
[102] E. B. Weiser, “The prevalence of anxiety disorders among
adults with asthma: a meta-analytic review,” Journal of Clinical
Psychology in Medical Settings, vol. 14, no. 4, pp. 297–307, 2007.
[103] M. Jiang, P.Qin, andX. Yang, “Comorbidity between depression
and asthma via immune-inflammatory pathways: a meta-
analysis,” Journal of Affective Disorders, vol. 166, pp. 22–29, 2014.
[104] J. De Miguel Diez, V. Hernandez-Barrera, L. P. Maestu, P. C.
Garrido, T. Gomez Garcia, and R. Jimenez Garcia, “Psychiatric
comorbidity in asthma patients. Associated factors,” Journal of
Asthma, vol. 48, no. 3, pp. 253–258, 2011.
[105] R. D. Goodwin, F. Jacobi, andW.Thefeld, “Mental disorders and
asthma in the community,” Archives of General Psychiatry, vol.
60, no. 11, pp. 1125–1130, 2003.
[106] C. Q. Jiang, A. Loerbroks, K.-B. H. Lam et al., “Mental health
and asthma in China: the Guangzhou Biobank Cohort Study,”
International Journal of Behavioral Medicine, vol. 20, no. 2, pp.
259–264, 2013.
[107] K. O. Wong, B. H. Rowe, J. Douwes, and A. Senthilselvan,
“Asthma and wheezing are associated with depression and
anxiety in adults: an analysis from 54 countries,” Pulmonary
Medicine, vol. 2013, Article ID 929028, 10 pages, 2013.
[108] W. J. Katon, L. Richardson, P. Lozano, and E. McCauley, “The
relationship of asthma and anxiety disorders,” Psychosomatic
Medicine, vol. 66, no. 3, pp. 349–355, 2004.
[109] M. J. Slattery and M. J. Essex, “Specificity in the association of
anxiety, depression, and atopic disorders in a community sam-
ple of adolescents,” Journal of Psychiatric Research, vol. 45, no.
6, pp. 788–795, 2011.
[110] I. Olssøn and A. A. Dahl, “Personality problems are con-
siderably associated with somatic morbidity and health care
utilisation,” European Psychiatry, vol. 24, no. 7, pp. 442–449,
2009.
[111] N. Iessa, M. L. Murray, S. Curran, and I. C. K. Wong, “Asthma
and suicide-related adverse events: a review of observational
studies,” European Respiratory Review, vol. 20, no. 122, pp. 287–
292, 2011.
[112] M. S. Pedersen, M. E. Benros, E. Agerbo, A. D. Børglum, and P.
B. Mortensen, “Schizophrenia in patients with atopic disorders
20 Mediators of Inflammation
with particular emphasis on asthma: a Danish population-
based study,” Schizophrenia Research, vol. 138, no. 1, pp. 58–62,
2012.
[113] K. M. Scott, M. V. Korff, J. Alonso et al., “Childhood adver-
sity, early-onset depressive/anxiety disorders, and adult-onset
asthma,” Psychosomatic Medicine, vol. 70, no. 9, pp. 1035–1043,
2008.
[114] J. Alonso, P. de Jonge, C. C. W. Lim et al., “Association between
mental disorders and subsequent adult onset asthma,” Journal
of Psychiatric Research, vol. 59, pp. 179–188, 2014.
[115] N. Hutter, A. Knecht, and H. Baumeister, “Health care costs
in persons with asthma and comorbid mental disorders. A
systematic review,” General Hospital Psychiatry, vol. 33, no. 5,
pp. 443–453, 2011.
[116] K. L. Lavoie, S. L. Bacon, S. Barone, A. Cartier, B. Ditto, and M.
Labrecque, “What is worse for asthma control and quality of life:
depressive disorders, anxiety disorders, or both?”Chest, vol. 130,
no. 4, pp. 1039–1047, 2006.
[117] K. L. Lavoie, M. Boudreau, A. Plourde, T. S. Campbell, and S. L.
Bacon, “Association between generalized anxiety disorder and
asthma morbidity,” Psychosomatic Medicine, vol. 73, no. 6, pp.
504–513, 2011.
[118] H. Favreau, S. L. Bacon, M. Labrecque, and K. L. Lavoie,
“Prospective impact of panic disorder and panic-anxiety on
asthma control, health service use, and quality of life in adult
patients with asthma over a 4-year follow-up,” Psychosomatic
Medicine, vol. 76, no. 2, pp. 147–155, 2014.
[119] A. ten Brinke, M. E. Ouwerkerk, A. H. Zwinderman, P. Spin-
hoven, and E. H. Bel, “Psychopathology in patients with severe
asthma is associated with increased health care utilization,”
American Journal of Respiratory and Critical Care Medicine, vol.
163, no. 5, pp. 1093–1096, 2001.
[120] K. Ouellet, S. L. Bacon, M. Boudreau, A. Plourde, G. Moullec,
and K. L. Lavoie, “Individual and combined impact of cigarette
smoking, anxiety, and mood disorders on asthma control,”
Nicotine & Tobacco Research, vol. 14, no. 8, pp. 961–969, 2012.
[121] M. Boudreau, S. L. Bacon, K. Ouellet, A. Jacob, and K. L. Lavoie,
“Mediator effect of depressive symptoms on the association
between BMI and asthma control in adults,” Chest, vol. 146, no.
2, pp. 348–354, 2014.
[122] S. G. Kapadia, C.Wei, S. J. Bartlett, J. Lang, R. A.Wise, and A. E.
Dixon, “Obesity and symptoms of depression contribute inde-
pendently to the poor asthma control of obesity,” Respiratory
Medicine, vol. 108, no. 8, pp. 1100–1107, 2014.
[123] M. B. Stein, B. J. Cox, T. O. Afifi, S.-L. Belik, and J. Sareen, “Does
co-morbid depressive illness magnify the impact of chronic
physical illness? A population-based perspective,” Psychological
Medicine, vol. 36, no. 5, pp. 587–596, 2006.
[124] A. van Huisstede, A. Rudolphus, A. van Schadewijk et al.,
“Bronchial and systemic inflammation in morbidly obese sub-
jects with asthma: a biopsy study,” American Journal of Respi-
ratory and Critical Care Medicine, vol. 190, no. 8, pp. 951–954,
2014.
[125] D. Desai, C. Newby, F. A. Symon et al., “Elevated sputum
interleukin-5 and submucosal eosinophilia in obese individuals
with severe asthma,” American Journal of Respiratory and
Critical Care Medicine, vol. 188, no. 6, pp. 657–663, 2013.
[126] I. H. van Veen, A. Ten Brinke, P. J. Sterk, K. F. Rabe, and E.
H. Bel, “Airway inflammation in obese and nonobese patients
with difficult-to-treat asthma,” Allergy, vol. 63, no. 5, pp. 570–
574, 2008.
[127] T. J. T. Sutherland, J. O. Cowan, S. Young et al., “The association
between obesity and asthma: interactions between systemic
and airway inflammation,” American Journal of Respiratory and
Critical Care Medicine, vol. 178, no. 5, pp. 469–475, 2008.
[128] W. C. Moore, A. T. Hastie, X. Li et al., “Sputum neutrophil
counts are associated with more severe asthma phenotypes
using cluster analysis,” The Journal of Allergy and Clinical
Immunology, vol. 133, no. 6, pp. 1557–1563.e5, 2014.
[129] J. R. O’Reilly and R. M. Reynolds, “The risk of maternal obesity
to the long-termhealth of the offspring,”Clinical Endocrinology,
vol. 78, no. 1, pp. 9–16, 2013.
[130] E. Forno, O.M. Young, R. Kumar, H. Simhan, and J. C. Celedo´n,
“Maternal obesity in pregnancy, gestational weight gain, and
risk of childhood asthma,” Pediatrics, vol. 134, no. 2, pp. e535–
e546, 2014.
[131] R. C. Johnson and R. F. Schoeni, “Early-life origins of adult
disease: national longitudinal population-based study of the
United States,” American Journal of Public Health, vol. 101, no.
12, pp. 2317–2324, 2011.
[132] C. J. Smith and K. K. Ryckman, “Epigenetic and developmental
influences on the risk of obesity, diabetes, and metabolic
syndrome,” Diabetes, Metabolic Syndrome and Obesity: Targets
and Therapy, vol. 8, pp. 295–302, 2015.
[133] P.D.Gluckman,M.A.Hanson, C. Cooper, andK. L.Thornburg,
“Effect of in utero and early-life conditions on adult health and
disease,” The New England Journal of Medicine, vol. 359, no. 1,
pp. 61–73, 2008.
[134] A. Danese, T. E. Moffitt, C. M. Pariante, A. Ambler, R. Poulton,
and A. Caspi, “Elevated inflammation levels in depressed adults
with a history of childhood maltreatment,” Archives of General
Psychiatry, vol. 65, no. 4, pp. 409–416, 2008.
[135] G. E. Miller and S. W. Cole, “Clustering of depression and
inflammation in adolescents previously exposed to childhood
adversity,” Biological Psychiatry, vol. 72, no. 1, pp. 34–40, 2012.
[136] P. F. Coogan, L. A. Wise, G. T. O’Connor, T. A. Brown, J. R.
Palmer, and L. Rosenberg, “Abuse during childhood and ado-
lescence and risk of adult-onset asthma in African American
women,” The Journal of Allergy and Clinical Immunology, vol.
131, no. 4, pp. 1058–1063, 2013.
[137] R. J. Van Lieshout, J. Bienenstock, and G. M. MacQueen,
“A review of candidate pathways underlying the association
between asthma and major depressive disorder,” Psychosomatic
Medicine, vol. 71, no. 2, pp. 187–195, 2009.
[138] L.G.Wood,K. J. Baines, J. Fu,H.A. Scott, andP.G.Gibson, “The
neutrophilic inflammatory phenotype is associated with sys-
temic inflammation in asthma,” Chest, vol. 142, no. 1, pp. 86–93,
2012.
[139] K. J. Baines, V. Backer, P. G. Gibson, H. Powel, and C. M.
Porsbjerg, “Impaired lung function is associated with systemic
inflammation andmacrophage activation,”TheEuropean Respi-
ratory Journal, vol. 45, no. 2, pp. 557–559, 2015.
[140] J. B. Morjaria, K. S. Babu, P. Vijayanand, A. J. Chauhan, D. E.
Davies, and S. T.Holgate, “Sputum IL-6 concentrations in severe
asthma and its relationship with FEV
1
,”Thorax, vol. 66, no. 6, p.
537, 2011.
[141] H. Kankaanranta, P. Ilmarinen, X. Zhang et al., “Tumour necro-
sis factor-𝛼 regulates human eosinophil apoptosis via ligation
of TNF-receptor 1 and balance between NF-𝜅B and AP-1,”
PLoS ONE, vol. 9, no. 2, Article ID e90298, 2014.
[142] C. A. Hunter and S. A. Jones, “IL-6 as a keystone cytokine in
health and disease,” Nature Immunology, vol. 16, no. 5, pp. 448–
457, 2015.
Mediators of Inflammation 21
[143] M. Rincon and C. G. Irvin, “Role of IL-6 in asthma and other
inflammatory pulmonary diseases,” International Journal of
Biological Sciences, vol. 8, no. 9, pp. 1281–1290, 2012.
[144] C. Irvin, I. Zafar, J. Good et al., “Increased frequency of
dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid
characterizes a population of patients with severe asthma,”The
Journal of Allergy and Clinical Immunology, vol. 134, no. 5, pp.
1175.e7–1186.e7, 2014.
[145] M. Jagannathan-Bogdan, M. E. McDonnell, H. Shin et al., “Ele-
vated proinflammatory cytokine production by a skewed T cell
compartment requires monocytes and promotes inflammation
in type 2 diabetes,” Journal of Immunology, vol. 186, no. 2, pp.
1162–1172, 2011.
[146] E. Fabbrini, M. Cella, S. A. McCartney et al., “Association
between specific adipose tissue CD4+ T-cell populations and
insulin resistance in obese individuals,” Gastroenterology, vol.
145, no. 2, pp. 366.e1–374.e3, 2013.
[147] V. Schmitt, L. Rink, and P. Uciechowski, “TheTh17/Treg balance
is disturbed during aging,” Experimental Gerontology, vol. 48,
no. 12, pp. 1379–1386, 2013.
[148] C. Brandenberger, N. Li, D. N. Jackson-Humbles, C. E. Rock-
well, J. G.Wagner, and J. R.Harkema, “Enhanced allergic airway
disease in old mice is associated with a Th17 response,” Clinical
& Experimental Allergy, vol. 44, no. 10, pp. 1282–1292, 2014.
[149] T. Wang, Y. Ji, Y. Yang et al., “Transcriptomic profiling of
peripheral blood CD4+ T-cells in asthmatics with and without
depression,” Gene, vol. 565, no. 2, pp. 282–287, 2015.
[150] O. J. G. Schiepers, M. C. Wichers, and M. Maes, “Cytokines
and major depression,” Progress in Neuro-Psychopharmacology
& Biological Psychiatry, vol. 29, no. 2, pp. 201–217, 2005.
[151] M. C. Wichers and M. Maes, “The role of indoleamine 2,3-
dioxygenase (IDO) in the pathophysiology of interferon-alpha-
induced depression,” Journal of Psychiatry & Neuroscience, vol.
29, no. 1, pp. 11–17, 2004.
[152] M. Haneklaus and L. A. O’Neill, “NLRP3 at the interface of
metabolism and inflammation,” Immunological Reviews, vol.
265, no. 1, pp. 53–62, 2015.
[153] M. Iwata, K. T. Ota, and R. S. Duman, “The inflammasome:
pathways linking psychological stress, depression, and systemic
illnesses,” Brain, Behavior, and Immunity, vol. 31, pp. 105–114,
2013.
[154] S. R. Kim, D. I. Kim, S. H. Kim et al., “NLRP3 inflammasome
activation by mitochondrial ROS in bronchial epithelial cells is
required for allergic inflammation,” Cell Death & Disease, vol.
5, no. 10, Article ID e1498, 2014.
[155] C.-B. Zhu, K. M. Lindler, A. W. Owens, L. C. Daws, R. D.
Blakely, andW.A.Hewlett, “Interleukin-1 receptor activation by
systemic lipopolysaccharide induces behavioral despair linked
to MAPK regulation of CNS serotonin transporters,”Neuropsy-
chopharmacology, vol. 35, no. 13, pp. 2510–2520, 2010.
[156] S. Ramamoorthy, J. D. Ramamoorthy, P. D. Prasad et al.,
“Regulation of the human serotonin transporter by interleukin-
1𝛽,” Biochemical and Biophysical Research Communications, vol.
216, no. 2, pp. 560–567, 1995.
[157] H. Y. Kim,H. J. Lee, Y.-J. Chang et al., “Interleukin-17-producing
innate lymphoid cells and the NLRP3 inflammasome facilitate
obesity-associated airway hyperreactivity,” Nature Medicine,
vol. 20, no. 1, pp. 54–61, 2014.
[158] T. J. T. Sutherland,M. R. Sears, C. R.McLachlan, R. Poulton, and
R. J. Hancox, “Leptin, adiponectin, and asthma: findings from
a population-based cohort study,” Annals of Allergy, Asthma &
Immunology, vol. 103, no. 2, pp. 101–107, 2009.
[159] M. Cano¨z, F. Erdenen,H.Uzun, C.Mu¨derrisoglu,, and S. Aydin,
“The relationship of inflammatory cytokines with asthma and
obesity,” Clinical and Investigative Medicine, vol. 31, no. 6, pp.
E373–E379, 2008.
[160] C. E. Ruhl and J. E. Everhart, “Leptin concentrations in the
United States: relations with demographic and anthropometric
measures,” The American Journal of Clinical Nutrition, vol. 74,
no. 3, pp. 295–301, 2001.
[161] O. Sideleva, B. T. Suratt, K. E. Black et al., “Obesity and asthma:
an inflammatory disease of adipose tissue not the airway,”
American Journal of Respiratory and Critical Care Medicine, vol.
186, no. 7, pp. 598–605, 2012.
[162] S. A. Shore, I. N. Schwartzman, M. S. Mellema, L. Flynt, A.
Imrich, and R. A. Johnston, “Effect of leptin on allergic airway
responses inmice,”The Journal of Allergy and Clinical Immunol-
ogy, vol. 115, no. 1, pp. 103–109, 2005.
[163] J. H. J. Vernooy, N. D. J. Ubags, G. G. Brusselle et al., “Leptin
as regulator of pulmonary immune responses: involvement in
respiratory diseases,” Pulmonary Pharmacology &Therapeutics,
vol. 26, no. 4, pp. 464–472, 2013.
[164] S. Leivo-Korpela, L. Lehtima¨ki, K. Vuolteenaho et al., “Adipok-
ine resistin predicts anti-inflammatory effect of glucocorticoids
in asthma,” Journal of Inflammation, vol. 8, article 12, 2011.
[165] A. Bruno, E. Pace, P. Chanez et al., “Leptin and leptin receptor
expression in asthma,” The Journal of Allergy and Clinical
Immunology, vol. 124, no. 2, pp. 237.e1–237.e4, 2009.
[166] J. H. Shin, J. H. Kim,W. Y. Lee, and J. Y. Shim, “The expression of
adiponectin receptors and the effects of adiponectin and leptin
on airway smooth muscle cells,” Yonsei Medical Journal, vol. 49,
no. 5, pp. 804–810, 2008.
[167] P. Ilmarinen and H. Kankaanranta, “Eosinophil apoptosis as a
therapeutic target in allergic asthma,” Basic & Clinical Pharma-
cology & Toxicology, vol. 114, no. 1, pp. 109–117, 2014.
[168] S. Conus, A. Bruno, and H.-U. Simon, “Leptin is an eosinophil
survival factor,”The Journal of Allergy and Clinical Immunology,
vol. 116, no. 6, pp. 1228–1234, 2005.
[169] H. Lai, N. Lin, Z. Xing, H. Weng, and H. Zhang, “Association
between the level of circulating adiponectin and prediabetes: a
meta-analysis,” Journal of Diabetes Investigation, vol. 6, no. 4, pp.
416–429, 2015.
[170] A. Sood, C. Qualls, M. Schuyler et al., “Low serum adiponectin
predicts future risk for asthma in women,” American Journal of
Respiratory and Critical Care Medicine, vol. 186, no. 1, pp. 41–47,
2012.
[171] A. Sood and S. A. Shore, “Adiponectin, leptin, and resistin in
asthma: basic mechanisms through population studies,” Journal
of Allergy, vol. 2013, Article ID 785835, 15 pages, 2013.
[172] S. K. Davis, S. Y. Gebreab, R. Xu et al., “Association of
adiponectin with type 2 diabetes and hypertension in African
American men and women: the Jackson Heart study,” BMC
Cardiovascular Disorders, vol. 15, article 13, 2015.
[173] A. Sood, E. Dominic, and C. Qualls, “Serum adiponectin is
associated with adverse outcomes of asthma in men but not in
women,” Frontiers in Pharmacology, vol. 2, article 55, 2011.
[174] K. M. Ajuwon and M. E. Spurlock, “Adiponectin inhibits LPS-
induced NF-𝜅B activation and IL-6 production and increases
PPAR𝛾2 expression in adipocytes,” The American Journal of
Physiology—Regulatory Integrative and Comparative Physiology,
vol. 288, no. 5, pp. R1220–R1225, 2005.
[175] E. J. Folco, V. Z. Rocha, M. Lo´pez-Ilasaca, and P. Libby,
“Adiponectin inhibits pro-inflammatory signaling in human
22 Mediators of Inflammation
macrophages independent of interleukin-10,” The Journal of
Biological Chemistry, vol. 284, no. 38, pp. 25569–25575, 2009.
[176] C. M. van Stijn, J. Kim, A. J. Lusis, G. D. Barish, and R.
K. Tangirala, “Macrophage polarization phenotype regulates
adiponectin receptor expression and adiponectin anti-inflam-
matory response,” The FASEB Journal, vol. 29, no. 2, pp. 636–
649, 2015.
[177] H. A. Periyalil, P. G. Gibson, and L. G. Wood, “Immuno-
metabolism in obese asthmatics: are we there yet?” Nutrients,
vol. 5, no. 9, pp. 3506–3530, 2013.
[178] O. L. Klein, J. A. Krishnan, S. Glick, and L. J. Smith, “Systematic
review of the association between lung function and Type 2
diabetes mellitus,”Diabetic Medicine, vol. 27, no. 9, pp. 977–987,
2010.
[179] B. G. J. Dekkers, D. Schaafsma, T. Tran, J. Zaagsma, and H.
Meurs, “Insulin-induced laminin expression promotes a hyper-
contractile airway smooth muscle phenotype,” American Jour-
nal of Respiratory Cell and Molecular Biology, vol. 41, no. 4, pp.
494–504, 2009.
[180] G. T. McMahon and R. A. Arky, “Inhaled insulin for diabetes
mellitus,”The New England Journal of Medicine, vol. 356, no. 5,
pp. 497–502, 2007.
[181] A. Agrawal, U. Mabalirajan, T. Ahmad, and B. Ghosh, “Emerg-
ing interface between metabolic syndrome and asthma,” Amer-
ican Journal of Respiratory Cell and Molecular Biology, vol. 44,
no. 3, pp. 270–275, 2011.
[182] S. Singh, Y. S. Prakash, A. Linneberg, and A. Agrawal, “Insulin
and the lung: connecting asthma and metabolic syndrome,”
Journal of Allergy, vol. 2013, Article ID 627384, 8 pages, 2013.
[183] P. Dandona, A. Aljada, P. Mohanty et al., “Insulin inhibits
intranuclear nuclear factor 𝜅B and stimulates I𝜅B in mononu-
clear cells in obese subjects: evidence for an anti-inflammatory
effect?” Journal of Clinical Endocrinology and Metabolism, vol.
86, no. 7, pp. 3257–3265, 2001.
[184] H. Ghanim, K. Green, S. Abuaysheh et al., “Suppressive effect
of insulin on the gene expression and plasma concentrations
of mediators of asthmatic inflammation,” Journal of Diabetes
Research, vol. 2015, Article ID 202406, 7 pages, 2015.
[185] M. Cazzola, L. Calzetta, P. Rogliani et al., “High glucose
enhances responsiveness of human airways smooth muscle via
the Rho/ROCK pathway,” American Journal of Respiratory Cell
and Molecular Biology, vol. 47, no. 4, pp. 509–516, 2012.
[186] W. W. Chance, C. Rhee, C. Yilmaz et al., “Diminished alveolar
microvascular reserves in type 2 diabetes reflect systemic
microangiopathy,” Diabetes Care, vol. 31, no. 8, pp. 1596–1601,
2008.
[187] H.O. Koskela, P. H. Salonen, and L.Niskanen, “Hyperglycaemia
during exacerbations of asthma and chronic obstructive pul-
monary disease,” Clinical Respiratory Journal, vol. 7, no. 4, pp.
382–389, 2013.
[188] E. Gulcan, I. Bulut, A. Toker, and A. Gulcan, “Evaluation of
glucose tolerance status in patients with asthma bronchiale,”
Journal of Asthma, vol. 46, no. 2, pp. 207–209, 2009.
[189] K. P. Dawson, A. C. Penna, and P. Manglick, “Acute asthma,
salbutamol and hyperglycaemia,” Acta Paediatrica, vol. 84, no.
3, pp. 305–307, 1995.
[190] P. M. O’Byrne, S. Rennard, H. Gerstein et al., “Risk of new
onset diabetes mellitus in patients with asthma or COPD taking
inhaled corticosteroids,” Respiratory Medicine, vol. 106, no. 11,
pp. 1487–1493, 2012.
[191] A. G. Desai, A. Togias, C. Schechter, B. Fisher, A. Parow, and
G. Skloot, “Peripheral airways dysfunction in obesity reflects
increased bronchomotor tone,” The Journal of Allergy and
Clinical Immunology, vol. 135, no. 3, pp. 820–822, 2015.
[192] A. Al-Alwan, J. H. T. Bates, D. G. Chapman et al., “The Non-
allergic asthma of obesity: a matter of distal lung compliance,”
American Journal of Respiratory and Critical Care Medicine, vol.
189, no. 12, pp. 1494–1502, 2014.
[193] J. H. T. Bates and A. E. Dixon, “Potential role of the airway wall
in the asthma of obesity,” Journal of Applied Physiology, vol. 118,
no. 1, pp. 36–41, 2015.
[194] A. Agrawal and Y. S. Prakash, “Obesity, metabolic syndrome,
and airway disease: a bioenergetic problem?” Immunology and
Allergy Clinics of North America, vol. 34, no. 4, pp. 785–796,
2014.
[195] A. Gardner, A. Johansson, R.Wibom et al., “Alterations of mito-
chondrial function and correlations with personality traits in
selected major depressive disorder patients,” Journal of Affective
Disorders, vol. 76, no. 1–3, pp. 55–68, 2003.
[196] C. C. Chang, S. H. Jou, T. T. Lin, T. Lai, C. Liu, and Y. Bai,
“Mitochondria DNA change and oxidative damage in clinically
stable patients with major depressive disorder,” PLoS ONE, vol.
10, no. 5, Article ID e0125855, 2015.
[197] M. K. Montgomery and N. Turner, “Mitochondrial dysfunction
and insulin resistance: an update,” Endocrine Connections, vol.
4, no. 1, pp. R1–R15, 2014.
[198] K. F. Petersen, D. Befroy, S. Dufour et al., “Mitochondrial
dysfunction in the elderly: possible role in insulin resistance,”
Science, vol. 300, no. 5622, pp. 1140–1142, 2003.
[199] U. Mabalirajan, A. K. Dinda, S. Kumar et al., “Mitochondrial
structural changes and dysfunction are associated with experi-
mental allergic asthma,”The Journal of Immunology, vol. 181, no.
5, pp. 3540–3548, 2008.
[200] L. Aguilera-Aguirre, A. Bacsi, A. Saavedra-Molina, A. Kurosky,
S. Sur, and I. Boldogh, “Mitochondrial dysfunction increases
allergic airway inflammation,” The Journal of Immunology, vol.
183, no. 8, pp. 5379–5387, 2009.
[201] E. K. Larkin, Y.-T. Gao, T. Gebretsadik et al., “New risk factors
for adult-onset incident asthma. A nested case-control study of
host antioxidant defense,” American Journal of Respiratory and
Critical Care Medicine, vol. 191, no. 1, pp. 45–53, 2015.
[202] I. Palomo, A. Contreras, L. M. Alarco´n et al., “Elevated concen-
tration of asymmetric dimethylarginine (ADMA) in individuals
withmetabolic syndrome,”Nitric Oxide: Biology and Chemistry,
vol. 24, no. 4, pp. 224–228, 2011.
[203] J. A. Scott, M. L. North, M. Rafii et al., “Asymmetric dimethy-
larginine is increased in asthma,” American Journal of Respira-
tory and Critical CareMedicine, vol. 184, no. 7, pp. 779–785, 2011.
[204] K. Krzyzanowska, F. Mittermayer, H.-P. Kopp, M. Wolzt, and
G. Schernthaner, “Weight loss reduces circulating asymmetrical
dimethylarginine concentrations in morbidly obese women,”
The Journal of Clinical Endocrinology and Metabolism, vol. 89,
no. 12, pp. 6277–6281, 2004.
[205] M. A. Mcevoy, P. Schofield, W. Smith et al., “Serum methy-
larginines and incident depression in a cohort of older adults,”
Journal of Affective Disorders, vol. 151, no. 2, pp. 493–499, 2013.
[206] M. L. Selley, “Increased (E)-4-hydroxy-2-nonenal and asym-
metric dimethylarginine concentrations and decreased nitric
oxide concentrations in the plasma of patients with major
depression,” Journal of Affective Disorders, vol. 80, no. 2-3, pp.
249–256, 2004.
Mediators of Inflammation 23
[207] F. Holguin, S. A. A. Comhair, S. L. Hazen et al., “An association
between L-arginine/asymmetric dimethyl arginine balance,
obesity, and the age of asthma onset phenotype,”American Jour-
nal of Respiratory and Critical Care Medicine, vol. 187, no. 2, pp.
153–159, 2013.
[208] L. Rochette, J. Lorin,M. Zeller et al., “Nitric oxide synthase inhi-
bition and oxidative stress in cardiovascular diseases: possible
therapeutic targets?” Pharmacology &Therapeutics, vol. 140, no.
3, pp. 239–257, 2013.
[209] S. M. Wells and A. Holian, “Asymmetric dimethylarginine
induces oxidative and nitrosative stress in murine lung epithe-
lial cells,” American Journal of Respiratory Cell and Molecular
Biology, vol. 36, no. 5, pp. 520–528, 2007.
[210] T. Ahmad, U. Mabalirajan, B. Ghosh, and A. Agrawal, “Altered
asymmetric dimethyl arginine metabolism in allergically
inflamedmouse lungs,”American Journal of RespiratoryCell and
Molecular Biology, vol. 42, no. 1, pp. 3–8, 2010.
[211] P. Ilmarinen, E. Moilanen, J. S. Erjefa¨lt, and H. Kankaanranta,
“The polyamine spermine promotes survival and activation
of human eosinophils,” The Journal of Allergy and Clinical
Immunology, vol. 136, no. 2, pp. 482.e11–484.e11, 2015.
[212] M. L. North, H. Grasemann, N. Khanna, M. D. Inman, G. M.
Gauvreau, and J. A. Scott, “Increased ornithine-derived poly-
amines cause airway hyperresponsiveness in a mouse model
of asthma,” American Journal of Respiratory Cell and Molecular
Biology, vol. 48, no. 6, pp. 694–702, 2013.
[213] Z. Bagi, A. Feher, H. Dou, and Z. Broskova, “Selective
up-regulation of arginase-1 in coronary arteries of diabetic
patients,” Frontiers in Immunology, vol. 4, article 293, 2013.
[214] M. L. North, N. Khanna, P. A. Marsden, H. Grasemann, and
J. A. Scott, “Functionally important role for arginase 1 in the
airway hyperresponsiveness of asthma,” American Journal of
Physiology—Lung Cellular and Molecular Physiology, vol. 296,
no. 6, pp. L911–L920, 2009.
[215] R. Spanbroek, R. Gra¨bner, K. Lo¨tzer et al., “Expanding expres-
sion of the 5-lipoxygenase pathway within the arterial wall dur-
ing human atherogenesis,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 100, no. 3, pp.
1238–1243, 2003.
[216] F. Cipollone,A.Mezzetti,M. L. Fazia et al., “Association between
5-lipoxygenase expression and plaque instability in humans,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no.
8, pp. 1665–1670, 2005.
[217] C. Pergola, G. Dodt, A. Rossi et al., “ERK-mediated regulation
of leukotriene biosynthesis by androgens: a molecular basis for
gender differences in inflammation and asthma,” Proceedings of
the National Academy of Sciences of the United States of America,
vol. 105, no. 50, pp. 19881–19886, 2008.
[218] M. Zaitsu, S.-I. Narita, K. C. Lambert et al., “Estradiol activates
mast cells via a non-genomic estrogen receptor-alpha and
calcium influx.,”Molecular Immunology, vol. 44, no. 8, pp. 1977–
1985, 2007.
[219] H. Kankaanranta, P. Ilmarinen, T. Kankaanranta, and L. E.
Tuomisto, “Seina¨joki Adult Asthma Study (SAAS): a protocol
for a 12-year real-life follow-up study of new-onset asthma
diagnosed at adult age and treated in primary and specialised
care,” NPJ Primary Care Respiratory Medicine, vol. 25, Article
ID 15042, 2015.
[220] P. Kirkham and I. Rahman, “Oxidative stress in asthma and
COPD: antioxidants as a therapeutic strategy,” Pharmacology &
Therapeutics, vol. 111, no. 2, pp. 476–494, 2006.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
